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Summary 
Angiogenesis, the formation of new blood vessels from preexisting vasculature, mainly 
occurs during embryonic development. In the adult it takes place in the female reproductive system 
and during wound healing. Unregulated angiogenesis is associated with various diseases such as 
atherosclerosis, retinopathies, lymphoproliferative or rheumatoid disease, and cancer. Tumor 
neovascularization enables cancer cells to enter the blood circulation and to metastasize to other 
organs and is a hallmark of many types of cancer. 
Vascular Endothelial Growth Factors (VEGFs) constitute a family of proteins that play an 
important role in blood and lymphatic vessel development. VEGFs interact with three type V 
receptor tyrosine kinases, VEGFR-1, -2, and -3 promoting endothelial cell survival, migration, 
proliferation, and differentiation. VEGFR-2 is the major mediator of angiogenic signaling in 
endothelial cells and its activity is regulated at multiple levels. Ligand binding to the extracellular 
domain (ECD) of VEGFR-2 leads to receptor dimerization followed by activation of the 
intracellular kinase domain and downstream signaling. However, at present the specific structural 
changes in the ECD and the exact molecular mechanisms underlying kinase activation are only 
partially understood. In this study, we investigated the role of ECD Immunoglobulin (Ig)-homology 
domains D4 and D7 in receptor dimerization and activation. We expressed a series of receptor ECD 
mutants in tissue culture cells and determined receptor activation. Mutation or deletion of D4 or D7 
drastically reduced receptor activation. We interpret these data as the demonstration that 
Ig-homology domains 4 and 7 are required for correctly aligning receptor monomers in active 
dimers and are thus indispensable for kinase activation.  
Based on our insights into the activation mechanism of VEGFR-2, we generated two types of 
ECD binders, single chain Fvs (scFvs) and Designed Ankyrin Repeat Proteins (DARPins), 
specifically interacting with single Ig-homology domains. We tested these reagents for inhibition of 
ligand-stimulated receptor activation. We identified several DARPins interacting with D2-3 and 
thereby blocking ligand binding and receptor activation. Most interestingly, DARPins binding to 
D4 inhibited receptor activation without interfering with receptor dimerization and therefore behave 
as allosteric regulators of VEGFR-2. Furthermore, scFvs specifically binding to D7 were identified. 
These new reagents will be useful for in vivo studies aiming at vessel imaging or for inhibiting 
VEGFR-2.  
We furthermore characterized variations in the VEGFR-2 gene which might contribute to the 
phenotypic variability in tumor endothelial function and, consequently, may affect cancer 
progression and the susceptibility of tumors to VEGFR-2 inhibitors. VEGFR-2 genomic sequencing 
ii  Summary 
 
 
 
in three different ethnic groups led to the discovery of 120 genetic variants, single nucleotide 
polymorphisms (SNPs), of which 25 had not been previously reported. The functionality of the 
genetic variants was assessed by phosphorylation assays, mRNA and protein expression arrays, as 
well as by the measurement of microvessel density in non-small cell lung cancer (NSCLC) tumor 
samples. The correlations found may have important implications for understanding the molecular 
basis of genetic associations between VEGFR-2 variation and clinical phenotypes related to 
VEGFR-2 function. 
Finally, we were interested in the influence of extracellular matrix components on 
VEGF-induced angiogenesis. In vivo, endothelial cells are exposed to concentration gradients of 
soluble growth factors and matrix immobilized guidance cues. To better mimic the complexity of 
angiogenic tissues in vitro, we generated micropatterned coverslips derivatized with VEGF for the 
cultivation of endothelial cells and the monitoring of their migration. Immobilized VEGF was 
shown to be biologically active and endothelial cells migrated and adhered to the patterned surfaces. 
The micropatterned coverslips present a robust and reproducible platform for the characterization of 
complex cellular behaviors generated by multiple VEGF isoforms. 
 
  
Summary   iii 
 
 
 
Zusammenfassung 
Die Bildung neuer Blutgefässe aus der bereits vorhandenen Vaskulatur, die sogenannte 
Angiogenese, tritt hauptsächlich während der Embryonalentwicklung auf. Beim erwachsenen 
Menschen kommt die Angiogenese sowohl im Fortpflanzungstrakt der Frau als auch in der 
Wundheilung auf natürliche Art und Weise vor. Unkontrollierte Angiogenese ist mit einer Vielzahl 
von Erkrankungen wie z.B Artheriosklerose, Retinopathien, lymphoproliferative oder rheumatoide 
Krankheiten sowie Krebs verbunden. Blutgefässneubildung im Tumor ermöglichen es den 
Tumorzellen in den Blutkreislauf zu gelangen und in andere lebenswichtige Organe zu 
metastasieren. Dieser Prozess ist ein Markenzeichen vieler Krebsarten. 
Vascular Endothelial Growth Factors (VEGFs) gehören zu einer Familie von Proteinen, die 
eine wichtige Rolle in der Bildung von Blut- und Lymphgefässen spielt. VEGFs interagieren mit 
drei Typ V Rezeptor Tyrosin Kinasen, den VEGFR-1, -2, und -3 und fördern das Überleben, die 
Migration, die Proliferation, und die Differenzierung von Endothelzellen. Der VEGFR-2 ist das 
hauptverantwortliche Protein in der Signalübertragung der Angiogenese und seine Aktivierung wird 
auf vielen verschiedenen Ebenen reguliert. Die Bindung seines Liganden an die extrazelluläre 
Domäne (ECD) des VEGFR-2 führt zu Dimerisierung des Rezeptors, gefolgt von der Aktivierung 
der intrazellulären Kinase-Domäne und des darunterliegenden Signaltransportweges. Die 
spezifischen, dabei zugrundeliegenden strukturellen Veränderungen in der ECD als auch die 
molekularen Mechanismen und Details der Kinase Aktivierung sind gegenwärtig jedoch nur 
teilweise erforscht. In meinem Forschungsprojekt haben wir die Rolle der extrazellulären 
Immunglobulin-ähnlichen Domänen 4 und 7 in der Rezeptor Dimerisierung und seiner Aktivierung 
untersucht. Verschiedene Rezeptor-ECD Mutanten wurden in kultivierten Zellen exprimiert und 
deren Grad der Rezeptor-Aktivierung bestimmt. Mutationen oder eine Deletion in der D4 
beziehungsweise D7 führten zu einer Reduktion der Rezeptor-Aktivierung. Wir interpretieren 
unsere Daten als Beweis dafür, dass die Ig-Homologie Domänen 4 und 7 für die korrekte 
Ausrichtung der Rezeptor Monomere, eine Grundvoraussetzung für die Aktivierung einer Kinase, 
in den aktiven Dimeren unverzichtbar sind. 
Basierend auf unseren Erkenntnissen über den Aktivierungsmechanismus des VEGFR-2 
haben wir zwei verschiedene Arten von ECD bindenden Reagenzien entwickelt, single chain Fvs 
(scFvs) und Designed Ankyrin Repeat Proteins (DARPins). Diese interagieren mit einzelnen 
Ig-Homologie Domänen mit hoher Spezifität und wurden auf ihre Fähigkeit der Inhibition der 
Liganden-stimulierten Rezeptor Aktivierung getestet. Es wurden mehrere DARPins identifiziert, 
welche die Bindung des Liganden in D2-3 blockierten und so eine Aktivierung des Rezeptors 
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verhinderten. Interessanterweise inhibierten D4 bindende DARPins die Rezeptor Aktivierung ohne 
gleichzeitig Einfluss auf die Dimerisierung des Rezeptors zu nehmen. Dieses Phänomen ähnelt 
einer Art allosterischen VEGFR-2 Regulation. Solche neuen Reagenzien sind sehr nützlich für die 
Bildanalyse von Blutgefässen oder das Inhibieren der VEGFR-2 Aktivierung in vivo.  
Darüber hinaus haben wir Variationen des VEGFR-2 Gens charakterisiert, welche bei der 
phänotypischen Variabilität in der Funktion des Tumorendothels und infolgedessen auch auf die 
Entwicklung von Krebserkrankungen wirken könnten. Diese Genvarianten könnten ausserdem die 
Empfindlichkeit gegenüber VEGFR-2 Inhibitoren beeinflussen. Sequenzierung von VEGFR-2 in 
der Keimbahn führte zur Entdeckung von 120 genetischen Varianten, sogenannter single nucleotide 
polymorphisms (SNPs). Davon waren bisher 25 nicht beschrieben. Die Funktionalität dieser 
genetischen Varianten wurde mit Hilfe von Phosphorylierungsassays, mRNA- und 
Proteinexpressionsassays bestimmt. Ausserdem wurde die Dichte der Mikrovaskulatur in non-small 
cell lung cancer (NSCLC) Tumorproben gemessen. Die beschriebenen Korrelationen könnten in der 
Zukunft helfen, die molekulare Basis genetischer Variationen zwischen VEGFR-2 Aktivierung und 
klinischen mit der VEGFR-2 Funktion assoziierten Phänotypen zu verstehen.  
Abschliessend interessierte uns der Einfluss von Bestandteilen der extrazellulären Matrix auf 
die VEGF-induzierte Angiogenese. Konzentrationsgradienten von Wachstumsfaktoren und 
matrix-immobilisierten Botenstoffe stellen die natürliche Umgebung von Endothelzellen in vivo 
dar. Um den komplexen Aufbau von angiogenem Gewebe in Zukunft besser in vitro imitieren zu 
können, generierten wir VEGF derivatisierte Mikromuster auf Deckgläsern. Diese Deckgläser 
dienten der Kultivierung von Endothelzellen und ermöglichten das Verfolgen der Zellmigration. Es 
konnte gezeigt werden, dass immobilisiertes VEGF weiterhin biologisch aktiv ist und dass 
Endothelzellen zu den vorgefertigten VEGF-Mustern migrieren und sich dort anheften. Unsere mit 
VEGF derivatisierten Deckgläser stellen eine robuste und reproduzierbare Plattform für die 
Charakterisierung von komplexen zellulären Verhalten dar, welche durch die vielfachen VEGF 
Isoformen generiert werden. 
 
1. Introduction  
 
 
 
1 
1 Introduction 
1.1 Angiogenesis 
1.1.1 Physiological and pathological angiogenesis 
The cardiovascular system is crucial for ensuring the delivery of nutrients and oxygen to all 
organs and tissues while at the same time being responsible for the disposal of catabolic products. 
The vasculature is also a major communication system between distant organs and tissues. 
Vasculogenesis and angiogenesis are the two key processes involved in the formation, development 
and maturation of the vascular system. 
Vasculogenesis is defined as the process of vessel formation in early development during 
which endothelial precursor cells, also known as angioblasts, differentiate into endothelial cells and 
form a primitive vascular plexus (Schmidt et al., 2007). Angiogenesis is the formation of new blood 
vessels from pre-existing vasculature. The process involves two main mechanisms known as 
splitting or intussusception and sprouting of vessels. During sprouting, endothelial cells of existing 
blood vessels secrete proteases which will degrade the underlying vessel basement membrane. 
Following degradation of the extracellular matrix (ECM), endothelial cells proliferate and extend 
“sprouts” into the surrounding tissue and towards the source of the angiogenic stimulus. The 
“leader” endothelial cells or non-dividing tip cells are followed by proliferating cells (Gerhardt et 
al., 2003). Finally, sprouting tubes fuse and form loops to build up a fully fledged vessel lumen that 
allows directional blood flow. Nascent vessels are stabilized by the recruitment of mural cells and 
vascular smooth muscle cells (Liekens et al., 2001). 
Physiological angiogenesis is not only observed in embryogenesis but also in the adult during 
the female reproductive cycle where follicular growth and corpus luteum formation require the 
proliferation of blood vessels (Hyder and Stancel, 1999). Vascular Endothelial Growth Factor 
(VEGF) is the main growth factor involved here (Ferrara et al., 1998). Furthermore, newly formed 
blood vessels also participate in the process of wound healing (Li et al., 2003). Fibroblast Growth 
Factor (FGF) and VEGF regulate neovascularization here (Ortega et al., 1998) (Nissen et al., 1998). 
In contrast, unregulated or pathological angiogenesis is a hallmark of various (over 20) 
malignant, ischemic, inflammatory, and infectious diseases. Insufficient angiogenesis contributes to 
ischemic heart disease (Shiojima et al., 2005), stroke (Krupinski et al., 1994), preeclampsia (Luttun 
and Carmeliet, 2003), and amyotrophic lateral sclerosis (Brockington et al., 2004). Excessive 
2  1. Introduction 
 
 
 
angiogenesis may lead to rheumatoid arthritis (Paleolog, 2002), psoriasis (Detmar, 2004), diabetic 
retinopathy (Shams and Ianchulev, 2006), and atherosclerosis (Celletti et al., 2001). A very serious 
disease accompanied by abnormal and excessive angiogenesis is cancer. Oxygen and nutrient 
supply guaranteed through an extensive network of capillaries is crucial for the growth of a tumor. 
When the tumor reaches a size of 1-2 mm in diameter, its demand for oxygen and nutrients exceeds 
the local supply. Limited oxygen supply from the surrounding blood vessels leads to a hypoxic 
microenvironment (Carmeliet and Jain, 2000). Subsequently, the hypoxia-inducible transcription 
factor HIF-1α is upregulated and activates the expression of many genes involved in angiogenesis 
such as VEGF and VEGFR-2 (Carmeliet et al., 1998). Many of the processes involved in tumor 
angiogenesis are similar to those occurring during physiological angiogenesis. However, due to 
tumor-secreted factors and tumor hypoxia, the angiogenic cascade in tumors is persistent and 
unresolved (Chung et al., 2010). The overproduction of VEGF leads to a leaky and haemorrhagic 
tumor vasculature. Another difference is the morphology of tumor vessels, which are disorganized 
and do not follow the hierarchical branching pattern of normal vascular networks. The newly 
formed blood vasculature in tumors enables the tumor cells to enter the blood circulation and 
metastasize to other organs (Fidler, 2000). 
Lymphangiogenesis, the formation of lymphatic vessels from pre-existing lymphatic vessels, 
plays a crucial role in homeostasis, metabolism, and immune surveillance of the body 
(Alitalo et al., 2005). It has been implicated in numerous pathologies (Jurisic and Detmar, 2009). 
Recently, it was shown that tumors can induce lymphangiogenesis by secreting growth factors 
which will then be drained to the sentinel nodes. Here, they lead to the formation of premetastatic 
niches (Hirakawa et al., 2007). 
 
1.1.2 Growth Factors, Receptors, Coreceptors in angiogenesis 
A detailed overview of coreceptors involved in VEGFR-mediated responses can be found in 
our review “Structure-function analysis of VEGF receptor activation and the role of coreceptors in 
angiogenic signaling” in appendix A (Grünewald et al., 2010). 
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1.2 Vascular Endothelial Growth Factor Receptor-2 
1.2.1 Vascular Endothelial Growth Factor Receptor-2 properties and signaling 
Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), originally known as Kinase 
insert domain-containing receptor (KDR) or fetal liver kinase-1 (Flk-1) is the central mediator of 
survival, migration, proliferation, maturation, and differentiation of endothelial cells. It binds 
VEGF-A, -C, -D, -E, and -F. VEGFR-2 is expressed on vascular and lymphatic endothelial and 
hematopoietic precursor cells, mature capillary endothelial cells, and neuronal cells. Gene-targeting 
of VEGFR-2 in the mouse leads to lethality at embryonic day (E) 8.5 due to defective blood island 
formation and arrested endothelial and hematopoietic development (Shalaby et al., 1995). The 
receptor is composed of seven Immunoglobulin (Ig)-homology domains in the extracellular domain 
(ECD), a single transmembrane region and a tyrosine kinase sequence interrupted by a kinase insert 
domain. Signaling by VEGFRs is initiated upon binding of a covalently linked ligand dimer to the 
extracellular receptor domain. This interaction promotes receptor homo- and heterodimerization 
followed by activation of the intracellular kinase domain. We have recently shown how VEGF 
induces dimerization of the extracellular receptor domain (Ruch et al., 2007). VEGFR-2 monomers 
are dimerized upon ligand binding to Ig-homology domains 2 and 3 and dimers are further 
stabilized by receptor-receptor contacts mediated by Ig-homology domains 4 and 7. Similar results 
were published by Schlessinger's laboratory for the related Kit, PDGF-, and VEGF-receptors 
(Yuzawa et al., 2007) (Yang et al., 2008) (Yang et al., 2010). We further demonstrated that 
artificial dimerization-promoting transmembrane domains (TMDs) derived from oncogenic variants 
of ErbB receptors activate VEGFR-2. Such TMD constructs orient receptor monomers by 
intra-membrane interactions mediated by charged amino acids (Dell'Era Dosch and 
Ballmer-Hofer, 2009). Receptor tyrosine kinase (RTK) activation thus requires specific orientation 
of receptor monomers in an active dimer which results from ligand-induced ECD rearrangement. 
Activation of RTKs leads to phosphorylation of specific tyrosine residues located in the 
intracellular juxtamembrane domain, the kinase domain, the kinase insert domain and the 
carboxyterminal tail of the receptor (Fig. 1-1). The subsequent interaction between VEGFRs and 
downstream signaling effectors is mediated through Src homology-2 (SH-2) and 
phosphotyrosine-binding (PTB) domains (reviewed in (Schlessinger and Lemmon, 2003)). 
Signaling by VEGF receptors has been reviewed comprehensively in recent review articles (Cébe-
Suarez et al., 2006b) (Shibuya and Claesson-Welsh, 2005); here we therefore refer only to some of 
the hallmarks of VEGFR-2 activation. 
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Figure 1-1: VEGFR-2 signaling and phosphorylation sites. 
Reprinted from (Olsson et al., 2006). 
 
 
Y951, Y1054, Y1059, Y1175 and Y1214 were identified as the most prominent 
phosphorylation sites of hVEGFR-2 (Matsumoto et al., 2005). Y1054 and Y1059 located in the 
activation loop of the kinase domain were classified as autophosphorylation sites important for the 
catalytic activity of the receptor kinase (Kendall et al., 1999). Site-directed mutagenesis led to the 
identification of Y801 and Y1175 as binding sites of phospholipase C-γ (PLC-γ1) (Cunningham et 
al., 1997). Phosphorylation and activation of PLC-γ1 gives rise to diacylglycerol and inositol 
trisphosphate which stimulate protein kinase C (PKC) (Nishizuka, 1984). Mitogenic signaling by 
VEGFR-2 is Ras independent and mediated by PKC via Erk kinases (Takahashi et al., 1999) 
(Doanes et al., 1999) (Wu et al., 2000a). VEGF-induced endothelial cell migration is mediated by 
the adaptor protein VRAP, also known as T cell-specific adaptor (TSAd) (Wu et al., 2000b). VRAP 
binding to Y951 leads to its phosphorylation and recruitment of Src kinase which promotes actin 
reorganization and cell migration (Matsumoto et al., 2005). Additionally, the adapter protein Shb 
binds to phosphorylated Y1175 and leads to phosphoinositide-3-kinase (PI3-kinase)-mediated 
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cytoskeleton reorganization as well as activation of focal adhesion kinase (FAK) (Holmqvist 
et al., 2004). Cell migration and capillary formation are regulated by VEGF through Gab1, which 
acts as an adaptor for Grb2, PI 3-kinase and the tyrosine phosphatase SHP2 (Laramee et al., 2007) 
(Dance et al., 2006). VEGF-induced actin remodeling is also triggered through the sequential 
activation of the small GTPase Cdc42 and stress activated protein kinase (SAPK/p38) following 
phosphorylation of Y1214 (Lamalice et al., 2004). This leads to phosphorylation and release of 
heat-shock protein 27 (HSP27). Early molecular events in cytoskeleton reorganization include 
recruitment of the adaptor protein Nck and the Src family kinase Fyn to VEGFR-2 and triggers 
phosphorylation of p21-activated protein kinase-2 (PAK2) and activation of Cdc42 and p38 MAPK 
(Lamalice et al., 2006). An additional important function of VEGF is survival signaling via 
activation of PI3-kinase and phosphorylation of Akt (Gerber et al., 1998). Finally, signaling by 
VEGFR-2 is important for endothelial cell specification, a process that might require activation of 
the Ras-Erk pathway (Kawasaki et al., 2008). 
 
1.2.2 Structure of VEGFs and VEGFR-2 extracellular domain 
Structural information on the ECD of VEGFRs is limited to the crystal structure of the 
Ig-homology domain 2 of VEGFR-1 in complex with VEGF-A (Wiesmann et al., 1997) 
(Starovasnik et al., 1999) or PlGF (Christinger et al., 2004), the Ig-homology domains 2 and 3 of 
VEGFR-2 in complex with VEGF-C (Leppanen et al., 2010), and the Ig-homology domain 7 of 
VEGFR-2 (Yang et al., 2010). D7 folds into a β-sandwich made up of two four-stranded sheets, the 
one composed of strands A, B, D, and E and the other of strands A´, G, F, and C. Hydrogen bonds 
are formed between A and B and A´ and G. The hydrophobic core buries a disulfide bridge between 
Cys688 in βB and Cys737 βF that connects the two β-sheets. A disulfide bridge is found between 
Cys740 in the βF and Cys745 in βG. Homotypic interactions suggested by the EM-structure of 
VEGFR-2 ECD (Ruch et al., 2007) (Fig. 1-2) have now been confirmed in the crystal structure.  
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Figure 1-2: Model for the activation of VEGFR-2. 
VEGF binds to VEGFR-2 and leads to dimerization of the receptor. Homotypic interactions in D7 and 
probably also D4 stabilize the dimers. Reprinted from (Ruch et al., 2007). 
 
 
Interactions are mediated by salt bridges formed between the positively charged Arg726 of 
one protomer and the negatively charged Asp731 of the other protomer in the loop region linking 
the βE and βF strands (Fig. 1-3). The contacts very strongly resemble the ones seen between D4 of 
the Kit receptor (Yuzawa et al., 2007). 
 
 
	
  
Figure 1-3: Homotypic VEGFR-2 domain 7 interface. 
Salt bridges are formed between Arg726 and Asp731 in the loop region between βE and βF strands in 
Ig-homology domain 7 of VEGFR-2. Reprinted from (Yang et al., 2010). 
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1.3 Anti-angiogenic therapy 
1.3.1 Available drugs for anti-angiogenic therapy 
In the 1970s, Dr. Judah Folkman of the Harvard Medical School suggested inhibiting new 
blood vessel formation as a way to fight cancer (Folkman, 1971). In the following years several 
therapies blocking angiogenesis have been developed and the first anti-angiogenic agents have now 
been approved for clinical use (reviewed in (Jain et al., 2006)). Inhibitors of the VEGF-pathway 
include monoclonal antibodies against the growth factors, small-molecule tyrosine kinase inhibitors 
(TKIs), and antibodies targeting the extracellular domain of the receptors.  
An example of an anti-angiogenesis drug targeting the growth factor is bevacizumab, a 
humanized monoclonal antibody against human VEGF-A (Presta et al., 1997) present on the market 
under the name Avastin® (Genentech, Inc., San Francisco, USA). Bevacizumab is intravenously 
administered to cancer patients and binds to all VEGF-A isoforms preventing their interaction with 
the receptors (VEGFR-1, -2, Nrp-1, and -2). This leads to inhibition of VEGFR-2 activation and 
blocks downstream signaling. As a result, angiogenesis at the tumor site is reduced and tumor 
growth slowed down. Bevacizumab has received Food and Drug Administration (FDA) approval 
for use in combination with chemotherapy in metastatic colorectal cancer (CRC) (Willett et al., 
2004) (Hurwitz, 2004), recurrent or metastatic non-small cell lung cancer (NSCLC) 
(Sandler, 2007), metastatic breast cancer (Miller et al., 2007) and renal cancer, and as a single agent 
in recurrent glioblastoma (GBM) (Friedman et al., 2009). It has been suggested that instead of 
blocking angiogenesis at the tumor site, bevacizumab rather leads to the normalization of abnormal 
blood vessels in the tumor environment and in this way allows an easier and more efficient delivery 
of jointly administered chemotherapeutics to the tumor (Jain, 2005) (Yang et al., 2005). In addition, 
bevacizumab is also used off-label to treat neovascular age-related macular degeneration (AMD) 
(Ciulla and Rosenfeld, 2009). AMD is caused by abnormal blood vessel growth beneath the macula 
which leads to severe loss of vision upon irreversible damage to the photoreceptors. An 
affinity-matured Fab fragment variant of bevacizumab known as ranibizumab (Lucentis®) has also 
received FDA-approval for the treatment of AMD (Ciulla et al., 2009). 
Tyrosine kinase inhibitors, the second group of anti-angiogenesis agents, target the 
ATP-binding site of the receptor tyrosine kinase (Traxler, 2003). Although TKIs such as sorafenib 
(Nexavar®, Bayer AG) and sunitinib (Sutent®, Pfizer) used against renal cell carcinoma have 
demonstrated antitumor activities, they present the disadvantage that they inhibit many kinase 
targets in addition to the VEGFRs. The lack of specificity for VEGFRs leads to a number of 
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“off-target” adverse effects in their long-term use (Shepard and Garcia, 2009). Therefore, one of the 
challenges is to develop more specific inhibitors against the individual VEGFRs. Since the different 
TKs are structurally very similar, a better option would be to target receptors at other unique site. 
The most clinically advanced VEGFR-2 inhibitor so far is Ramucirumab (IMC-1121B, 
ImClone Systems, New York, USA), a fully human monoclonal antibody against the ligand-binding 
domain of VEGFR-2 (Spratlin, 2011). It was developed from IMC-1C11, a mouse-human chimeric 
antibody which proved to be successful but showed side effects associated with chimeric antibodies 
in early clinical trials. To circumvent these adverse effects, IMC-1C11 was later fully humanized to 
IMC-1121B. IMC-1121B will shortly be entering phase II and III clinical trials. However, the main 
disadvantage of inhibitors that bind to the ligand-binding domain of receptors is that they need to 
compete with the ligand and are therefore only effective when ligand-concentration is low. 
Despite the success of anti-angiogenic drugs in prolonging the life of cancer patients, two 
studies have now shown that VEGF-targeted drugs inhibit primary tumor growth but elicit tumor 
invasiveness and metastasis (Paez-Ribes et al., 2009) (Ebos et al., 2009). Explanations for this 
could be that compared to normal cells tumor cells tolerate hypoxia better but are also capable of 
escaping hypoxia (discussed in (Loges et al., 2009)). Escape mechanisms include metabolic 
reprogramming to glucose addiction in hypoxic conditions (Brahimi-Horn et al., 2001), co-option 
of existing vasculature (Bergers and Hanahan, 2008), or selection of hypoxia-tolerant tumor cell 
clones (Brahimi-Horn et al., 2001). Drug resistance may also arise from compensatory activation or 
the overexpression of a different cell signaling protein. A VEGF-independent vascular regrowth has 
been observed with concurrent upregulation of FGF family ligands. A potential strategy against this 
resistance could be to target multiple angiogenic signaling pathways simultaneously. 
 
 
1.3.2 Antibodies in the clinic 
1.3.2.1 Definition of an antibody 
Antibodies are proteins involved in specific immune recognition and their functions are to 
bind specifically to pathogens (bacteria, virus) and to recruit other cells are required to destroy 
pathogens or pathogen containing host cells. Antibodies are produced by B cells and occur in two 
forms, either soluble or membrane-bound. They consist of two parts, the variable region which is 
the antigen-binding region and the constant region which is responsible for engaging the effector 
functions of the immune system. An antibody molecule is made up of two heavy (50 kDa each) and 
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two light chains (25 kDa each) joined by disulfide bridges. Each heavy chain is linked to a light 
chain and the two heavy chains are linked to each other. The heavy chains are composed of a 
variable (VH) and three constant domains (CH1-3) whereas the light chains consist of one variable 
(VL) and one constant domain (CL). The variable regions VH and VL contain the so-called 
hypervariable regions or complementary determining regions (CDRs) which form the antigen 
binding site and determine antibody specificity.  
Fully human monoclonal antibodies (mAbs) are a promising and rapidly growing category of 
targeted therapeutic agents. In 1975, Köhler and Milstein established the method of generating 
monoclonal antibodies by hybridomas (Kohler and Milstein, 1975). For this, spleen cells of an 
immunized mouse are fused to cells of a mouse myeloma, a common tumor of plasma cells. These 
hybrid myeloma cells or hybridomas proliferate indefinitely and secrete antibodies specific for the 
antigen used to immunize the mouse. For therapeutic applications in humans, the disadvantages of 
murine antibodies are their safety as well as the immunogenicity of the mouse-derived protein 
sequences. Establishing human hybridomas and the production of human mAbs from human cell 
lines proved to be difficult (Cole et al., 1984) (Pasqualini and Arap, 2004). Therefore, several 
alternative strategies have been followed to produce human mAbs. To reduce the immunogenicity 
of murine antibodies, chimeric and humanized mAbs containing murine variable regions linked to 
human constant regions were engineered (Riechmann et al., 1988). Another approach to obtain 
humanized antibodies is the production of monoclonal antibodies in so-called “Xenomice”, 
transgenic mice that carry human immunoglobulin gene loci (Green, 1999). 
Finally, antibodies can be obtained by selection of human antibody fragments from 
phage-display libraries (McCafferty et al., 1990). 
 
1.3.2.2 Phage Display 
Phage display libraries may be used to raise human antibodies against a variety of antigens, 
including toxic, highly pathogenic, or non-immunogenic targets. The gene encoding a specific 
antibody-like polypeptide is inserted into the genome of a phage and as a result the peptide is 
displayed on the phage surface. Large repertoires, so-called phage libraries, can be generated where 
each polypeptide expressed on the surface of a phage has a different sequence (Pini et al., 1998). 
Filamentous bacteriophages such as M13 are used for the technology of phage display and allow the 
linking of phenotype (displayed protein) to genotype (inserted gene encoding the protein). M13 is a 
bacterial virus that infects many gram-negative bacteria. The phage is composed of five coat 
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proteins (pIII, pVI, pVII, pVIII, and pIX) of which the minor coat protein pIII is most often used for 
the phage display fusions. pIII is expressed in five copies at the tip of the phage and is responsible 
for attachment of the phage to the f pilus of bacteria during infection. Following attachment, the 
viral ssDNA is translocated into the bacterial cytoplasm, converted into dsDNA from which phage 
genes are subsequently expressed. New virions are now assembled and secreted from the bacteria. 
Phagemid vectors containing only the gene III, cloning sites and packaging signal, have nowadays 
replaced the initial phage vectors. Since phagemid vectors lack some of the phage genes, 
superinfection of the E.coli with helper phages such as VCSM13 or M13KO7 is required for the 
production of functional phage particles. The antigen of interest is immobilized onto a support such 
as a plastic tube for example and the library of single chain Fv (scFv)-displaying phages is run over 
it. After panning, unbound phages are washed away and specific phages are eluted and collected. 
They are amplified by infection of bacteria and used for further rounds of selection (Fig. 1-4). 
Usually after two to three selection rounds, clones are tested for their specificity by enzyme-linked 
immunosorbant assay (ELISA). Instead of selecting antibodies against immobilized antigens, 
antigens can be biotinylated and antibodies selected in solution. This circumvents the problem that 
in some cases antigens change their conformation when immobilized on solid surfaces. 
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Figure 1-4: Selection of single chain Fvs from a phage display library. 
Phages displaying binding proteins (red, green, yellow) on their surface are captured on immobilized antigen. 
Unbound phages are washed away and binding phages are eluted. Amplification occurs in E.coli after 
infection of the bacteria with the eluted phages. Enriched phages are used for further rounds of selection. 
Screening of eluted binders is performed after two to three selection rounds.  Original artwork inspired by 
(Marasco and Sui, 2007). 
 
 
1.3.2.3 ETH-2 Gold Library 
The ETH-2 Gold antibody phage display library is a synthetic human antibody library in the 
single-chain Fv (scFv) format. The library was established and constructed in the group of 
Prof. Dario Neri at the ETHZ (Silacci et al., 2005). A scFv fragment is made up of a single 
polypeptide chain consisting of an antibody heavy variable domain (VH) linked by a flexible 
polypeptide linker to a light chain variable domain (VL). ScFvs have a molecular weight of about 
30 kDa and are not glycosylated. In order to obtain the 3 x 109 individual clones that make up a 
complex library, sequence variability was introduced into the CDR3 regions of both the heavy and 
the light chains. PCR with partially degenerate primers was used to generate random mutations in 
the CDR3 of the heavy chain DP47 and the CDR3 of the light chains DPL16 or DPK22. Variability 
Phages 
Washing 
Binding 
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in the CDR3 of the DP47 segment consists of four to six randomized amino acids at positions 
95-100. In the CDR3 of DPL16, six amino acids were randomized with at least one residue being a 
proline. In the CDR3 of DPK22, the second or third residue of the six is a glycine and the fifth 
residue a proline (Fig. 1-5). The flexible polypeptide Gly4SerGly4SerGly4 (Huston et al., 1988) was 
used as a linker between the two variable fragments.  
 
 
	
  
 
Figure 1-5: Variable heavy and light chain sequence design in a scFv (ETH-Gold-2 library). 
Variability is obtained by random sequences (X) in the human VH (DP47) and VL (DPK22 or DPL16) antibody 
germline segments as indicated. VH and VL sequences are joined by a linker. ScFvs carry a myc affinity-tag. 
pIII encodes the phage coat protein to which the scFv is fused. An amber stop codon is found between the 
scFv- and the pIII-sequence. Reprinted from (Silacci et al., 2005). 
 
 
The VH-VL combinations were cloned into the phagemid vector (pHEN1) (Hoogenboom, 1991). 
The pHEN1 vector is composed of an upstream bacterial periplasmic secretion signal (pelB), a 
downstream myc-tag (EKQLISEEDL) fused to the C-terminus of the scFv, a suppressible amber 
stop codon (TAG) and the phage coat protein gene pIII (Fig. 1-6). 
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Figure 1-6: pHEN1 expression plasmid. 
The pHEN1 phagemid containing a bacterial periplasmic secretion signal (pelB), a colE1 ori, and an M13 
phage origin of replication is used for the expression of scFvs (VH-linker-VL). 
Modified from (Silacci et al., 2005). 
 
 
When amber- or supE-suppressor E. coli strains are infected with phage, the translation will 
read through the amber stop codon and a fusion protein consisting of the scFv and the pIII coat 
protein will be produced. In a non-supE suppressor strain, only soluble scFv protein will be 
produced and secreted into the periplasmic space. ScFvs will leak into the supernatant in part due to 
their cytotoxicity in E. coli. Protein A can be used to purify the scFvs from the supernatant via 
affinity chromatography. 
 
 
1.3.3 Designed Ankyrin Repeat Proteins 
1.3.3.1 Definition of a Designed Ankyrin Repeat Protein 
Designed Ankyrin Repeat Proteins (DARPins) are genetically engineered antibody mimetic 
proteins derived from natural ankyrin proteins (Fig. 1-7). They were developed at the University of 
Zürich by the group of Prof. Plückthun (Binz et al., 2003). Like their natural counterparts, DARPins 
bind specifically and with high-affinity to target proteins. They consist of two to four repeat motifs 
which are genetically fused and flanked by an N- and a C- capping repeat. The role of the caps is to 
bury the hydrophobic core. Each library module consists of an ankyrin repeat of 33 amino acids of 
which seven are variable. The molecular mass of DARPins ranges from 14 to 21 kDa, depending on 
the number of modules. DARPins show very high expression levels in E. coli, are soluble and 
exhibit high stability (Binz et al., 2003). The DARPin scaffold does not contain any cysteines, these 
can therefore be added for site-directed coupling of a variety of chemicals such as cytotoxins for 
!"amber codon 
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example. This opens the possibility to use DARPins as therapeutic agents. DARPin® MP0112 a 
potent VEGF-A inhibitor developed by Molecular Partners AG, has now entered clinical trials for 
the treatment of Diabetic Macular Edema (http://www.clinicaltrials.gov/show/NCT01042678) and 
Wet Age-Related Macular Degeneration (http://www.clinicaltrials.gov/ct2/show/NCT01086761).  
Advantages of therapeutic DARPins over antibodies include higher stability, low-cost 
production, better tissue penetration due to the smaller size of the DARPins (18 kDa versus 
150 kDa for an IgG), and the absence of effector function and therefore low risk of immunogenicity 
(Stumpp and Amstutz, 2007) (Stumpp et al., 2008). In most of the cases, DARPins bind their target 
proteins on a conformational epitope. The protein is therefore forced to remain in this specific 
conformation and in this way allows allosteric inhibition through the DARPin. 
 
 
	
  
Figure 1-7: Scheme of DARPin library design. 
Two caps (N- and C-Cap) and a variable number of library modules (n=2-4) make up a DARPin molecule. 
Library modules consist of an ankyrin repeat of 33 amino acids with seven variable positions. The size of a 
DARPin molecule typically ranges between 14 and 21 kDa. 
Reprinted from (Stumpp et al., 2008) . 
  
To take advantage of ankyrin repeat proteins as alternatives to
antibody-based scaffolds, DARPin libraries were engineered by a
consensus design approach [13]. Natural ankyrin repeat protein
sequences, 229 ankyrin repeats for the initial design and another
2200 for subsequent refinement, were used in a consensus design
approach to define a DARPin library module, which served as a
building block for the DARPin libraries [14] (Figure 1). Since many
sequences used for this approach were derived from the human
genome, the designed library module closely resembled human
sequences (!67% identity, !71% similarity to human GA binding
Protein, Uniprot ID Q06547). Different numbers of these modules
are then genetically fused and flanked by capping repeats, shield-
ing the continuous hydrophobic core of the repeat domain, giving
rise to N"C DARPin libraries (Figure 1), where N stands for the N-
terminal capping repeat, C for the C-terminal capping repeat
and " for the number of library modules, typically ranging
between two and four [14]. Since single library modules are built
from 33 amino acids, of which seven are variable, resulting in a
diversity ofmore than 10million permodule, the libraries carrying
two of these repeat modules reach diversities of well above 1014.
Since the molecular weight of one module is just above 3.5 kDa
and DARPins are composed of four to six modules, their molecular
weight ranges from 14 to 21 kDa, which is approximately one
tenth of the size of a conventional IgG antibody, or one third of the
size of the Fab fragment, the smallest antibody fragment currently
approved for therapeutic use [15].
The consensus design approach not only helped to design large
libraries, but also yielded idealized DARPins with improved prop-
erties, such as very high expression levels, high stability and
solubility [12,14]. Expression of functional DARPins can be per-
formed in the cytoplasm of Escherichia coli (E. coli) with yields
reaching 200 mg/l purified protein in simple shake flask cultures in
the low expressor strainXL1-blue (14). Further, the production can
be improved by using specialized expression strains (e.g. BL21) and
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FIGURE 1
Scheme of the DARPin library design, the resulting DARPin molecules and the target protein binding. (a) DARPin libraries are composed of two caps (N- and C-)
and a varying number of library modules (n), all shown as grey ribbon representation with a transparent space fill surface. Each library module corresponds to an
ankyrin repeat of 33 amino acids, where seven positions are variable, displayed as red side chains (diversity > 107). Typically, two to four library modules (n = 2–4)
are combined into one protein domain (diversity > 1014), giving rise to DARPins between 14 and 21 kDa, respectively, which is about one tenth the size of a
conventional antibody. (b) The three dimensional representation of two DARPins, both with three librarymodules, is shown. The blue and red colouring highlights
the randomized surface for potential target interaction. (c) Two DARPin target protein complexes are shown (MBP, maltose binding protein and DARPin off7 PDB:
1SVX; APH aminoglycoside phosphotransferase and DARPin AR_3A, PDB: 2BKK). The targets are bound by the randomized target interaction surface of the
DARPins (coloured in red and blue, respectively), thus resembling the natural target-binding mode, indistinguishable from natural ankyrin repeat proteins [18].
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1.3.3.2 Ribosome Display 
The technique of ribosome display was first described by Mattheakis et al. in 1994 
(Mattheakis et al., 1994). Ribosome display begins with the transcription of linear DNA fragments 
encoding a protein library (Fig. 1-8). Subsequently, translation of the mRNA takes place in vitro. 
Due to the absence of a stop codon in the mRNA (Hanes and Pluckthun, 1997), the ribosome does 
not detach from the mRNA and a ternary complex composed of the ribosome, the mRNA and the 
nascent polypeptide is formed. The complex is stabilized by lowering the temperature and adding 
cations. It is directly used for affinity selection with a ligand which is either immobilized or in 
solution. The mRNA contained in the bound ribosomal complexes is eluted by addition of EDTA. It 
is then purified, reverse-transcribed, and amplified by PCR. Like phage display, this technique 
allows the coupling of genotype (RNA, DNA) and phenotype (protein). Being an in vitro display 
technology, ribosome display has two advantages over other selection strategies. First, very high 
library diversity can be achieved since there is no limitation arising from the transformation 
efficiency of bacterial cells. Second, mutations leading to a high diversity can easily be introduced 
by PCR-based mutagenesis during the PCR step in the selection round. 
 
	
  
Figure 1-8: Ribosome display technology. 
Transcription of DNA fragments encoding a protein library is followed by translation. Since the mRNA does 
not contains a stop codon, the ribosome will not dissociate and forms a stable complex with the translated 
protein and the mRNA. The ternary complex of mRNA, ribosome, and nascent polypeptide is used for 
selection. Eluted mRNA is reverse transcribed and DNA used for the next selection round. Reprinted from 
(Zahnd et al., 2004). 
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1.4 Aim of the thesis 
The inhibition of new blood vessel formation is a very promising therapeutic approach in the 
fight against cancer. Given the key importance of VEGFR-2 in angiogenesis, promising 
anti-angiogenic therapies aim at targeting this receptor and blocking its downstream signaling. A 
detailed understanding of the VEGFR-2 activation mechanism is a crucial prerequisite for the 
development of specific anti-angiogenic drugs in biomedical research. 
VEGFR-2 is activated upon ligand-binding to the extracellular domain (ECD). Receptor 
dimerization follows ligand-binding and promotes activation of the intracellular kinase domain 
which leads to downstream signaling. At present, the specific structural changes in the ECD and the 
exact mechanisms responsible for kinase activation are only partially understood. The work 
presented in my thesis is focused on an investigation of the activation mechanism of VEGFR-2 
aiming at a detailed functional investigation of the role of ECD membrane-proximal Ig-homology 
domains 4 and 7 in VEGFR-2 activation. Based on our functional analysis of VEGFR-2 activation, 
we further aimed at the generation of specific inhibitors binding to D4 and D7 of the ECD that 
might block receptor activation. We generated two different types of inhibitors. We used the 
synthetic ETH-2 gold library to identify scFv inhibitors against D7 and, in collaboration with 
Molecular Partners AG in Schlieren, we developed DARPins interacting with the receptor ECD. 
In a second project, we were interested in characterizing variations in the VEGFR-2 gene 
which might contribute to the phenotypic variability in tumor endothelial function and, 
consequently, may affect cancer progression and the susceptibility of tumors to VEGFR-2 
inhibitors.  
My third project aimed at the development of a new cell culture technology based on growing 
cells on micropatterned substrates for monitoring VEGF-induced angiogenesis in vitro. I used two 
different methodologies to generate micropatterned coverslips for cultivation of endothelial cells. 
These substrates mimic the in vivo environment and allow the application of gradients of different 
VEGF isoforms to endothelial cell cultures. Different concentrations of soluble or matrix-bound 
VEGF will be used for monitoring endothelial cell migration. 
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2 Structure–function analysis of VEGF receptor activation and the role of 
coreceptors in angiogenic signaling 
 
 
 
The full manuscript can be found in appendix A.  
My contribution to this manuscript was the writing of chapter “VEGF receptor activation and 
signaling” (1.3.). 
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3.1 Abstract 
Vascular Endothelial Growth Factors (VEGFs) regulate blood and lymph vessel formation by 
activating three receptor tyrosine kinases, VEGFR-1, -2 and -3. The extracellular ligand-binding 
domain of VEGFRs consists of seven immunoglobulin homology domains (Ig domains) connected 
by a transmembrane helix to the intracellular tyrosine kinase domain. VEGF family ligands interact 
with Ig domains 2 and 3 thereby inducing receptor dimerization. Low resolution structural 
information and biophysical data show that specific orientation of receptor monomers in active 
dimers is further controlled by homotypic receptor contacts mediated through membrane-proximal 
Ig domains. Investigating the role of this membrane proximal part of the extracellular domain in 
receptor activation we found that Ig domains 4 and 7 are required for properly aligning receptor 
monomers in active dimers and are thus indispensable for kinase activation. We developed 
Designed Ankyrin Repeat Proteins (DARPins) specifically binding to the extracellular receptor 
domain. DARPins specific for Ig domains 2 and 3 inhibited ligand binding while DARPins specific 
for Ig domain 4 prevented kinase activation without interfering with dimerization. These data reveal 
a crucial role for the membrane-proximal receptor domain in ligand-mediated activation of 
VEGFR-2.  
 
 
3.2 Introduction 
Receptor tyrosine kinases (RTKs) fulfill essential functions in a wide variety of biological 
processes such as cell growth, differentiation, migration and survival. Regulation of RTKs is the 
subject of intense research since it holds promise for the development of new drugs aiming at 
diseases caused by deregulation of RTK activity. Vascular Endothelial Growth Factors, VEGFs, 
comprise a family of proteins interacting with three type V RTKs, VEGFR-1 (Flt-1), VEGFR-2 
(KDR/Flk-1), and VEGFR-3 (Flt-4) (Pajusola et al., 1992;Shibuya et al., 1990;Terman et al., 1991). 
VEGFs promote endothelial cell survival, migration, proliferation, and differentiation, and are thus 
indispensable for blood and lymph vessel formation. In addition, VEGFs regulate endothelial cell 
permeability and vessel contraction. Like all RTKs, VEGFRs are activated following ligand-
induced structural changes in the receptor extracellular domain (ECD) (reviewed in (Grünewald et 
al., 2010). VEGFR-2 is the major mediator of angiogenic signaling in endothelial cells (Shalaby et 
al., 1995) and its activity is regulated at multiple levels. We have also shown that receptor 
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dimerization is necessary, but not sufficient, for receptor kinase activation (Dell'Era Dosch 
et al.,  2009). These data clearly demonstrate that specific orientation of receptor monomers in the 
active dimers is required to instigate transmembrane signaling and kinase activation. 
High resolution structures of ligand-receptor complexes of VEGFRs show that Ig homology 
domains 2 and 3 comprise the ligand binding site (Christinger et al., 2004;Leppanen 
et al., 2010;Wiesmann et al., 1997). In addition, our laboratory published an electron microscopy 
structure of the full length ECD of VEGFR-2 bound to VEGF (Ruch et al., 2007). This structure 
was recently confirmed by a structural model derived from a small angle solution scattering (SAXS) 
analysis (Kisko et al. accepted). Taken together, our data demonstrate that receptor monomers are 
not only held together by ligand binding to Ig domains 2 and 3, but by additional homotypic 
receptor contacts formed by the membrane-proximal part of the ECD.  
Here we extend earlier studies investigating the role played by the individual extracellular 
Ig homology domains in ligand binding (Shinkai et al., 1998) and receptor activation (Tao 
et al., 2001;Yang et al., 2010).  Based on our own work (Ruch et al., 2007), we analyzed the 
function of Ig homology domains D4 and D7 in receptor dimerization and activation. We created a 
series of receptor ECD mutants that were expressed in tissue culture cells for determining receptor 
activity. Mutation or deletion of D4 and D7 drastically reduced receptor activity. Based on these 
results we developed new ECD binders, Designed Ankyrin Repeat Proteins (DARPins), specifically 
interacting with single Ig homology domains. By testing these reagents for inhibition of ligand-
stimulated receptor activity we identified several DARPins binding to D2-3 and thereby blocking 
ligand binding and receptor activation. Most interestingly, DARPins binding to D4 efficiently 
inhibited receptor activation without interfering with dimerization. These new reagents will be 
useful for in vivo studies aiming at imaging or inhibiting VEGFR-2. 
 
  
22 3. Inhibition of receptor activation by Designed Ankyrin Repeat Proteins 
 
 
 
3.3 Materials and Methods 
3.3.1 Cloning of VEGFR-2 mutants 
The pcDNA5/FRT vector (Invitrogen) was used for the expression of VEGFR-2 mutants in 
HEK293 and COS-1 cells. The pcDNA5/FRT VEGFR-2 3/5 construct was generated by 
PCR-subcloning (Geiser et al., 2001). Ig-homology D5 was PCR-amplified from the pcDNA3.1 
VEGFR-2 wt construct (in-house) using the primers listed in the appendix table 1 and subcloned 
into the pcDNA5 FRT VEGFR-2 wt plasmid to replace D4. The pcDNA5 FRT VEGFR-2 Δ4 and 
K868M constructs were kindly provided by Claudia Ruch (in-house). 
Mutations R726A, D731, RD/AA, and xD7EF were introduced into the pcDNA5 
FRT VEGFR-2 wt construct by PCR-subcloning (Geiser et al., 2001) with primers containing the 
mutations (Suppl. Table 3-1). 
The pLIB vector derived from Moloney murine leukemia virus was used for the retroviral 
transduction of PAE cells. The pLIB LN VEGFR-2 and the pVSV-G plasmids were kindly 
provided by Ralph Graeser (ProQinase GmbH Freiburg, Germany). For generating pLIB LN 
VEGFR-2 wt, 3/5, R, D, RD, and xD7EF constructs, the sequences were PCR-amplified from the 
respective constructs in the pcDNA5/FRT vector by simultaneously introducing a SalI restriction 
site. Primers are listed in Suppl. Table 3-2. Insert and pLIB LN vector were joined by standard 
ligation process. 
Mutations RRR/AAA, RRRK/AAAS, ED/AA, and EDE/AAA were introduced into both the 
pcDNA5 FRT VEGFR-2 wt and pLIB LN VEGFR-2 wt constructs by PCR-subcloning (Geiser et 
al., 2001) with primers containing the mutations (Suppl. Table 3-3). 
 
3.3.2 Cell culture 
Human embryonic kidney epithelial cells 293 (HEK 293), COS-1 monkey kidney cells and 
bovine aortic endothelial cells (BAECs) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM, BioConcept) supplemented with 10% fetal bovine serum (FBS) or 10% newborne calf 
serum (NCS) in the case of the BAECs. Porcine aortic endothelial cells (PAE cells) were 
maintained in Ham’s F12 medium (BioConcept) containing 10% FBS. Cells were grown in a 
humidified atmosphere at 37 °C and 5% CO2. 
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3.3.3 Transfection of HEK293 and COS-1 cells 
Transfection of HEK293 cells or COS-1 cells with FuGENE (FuGENE HD Transfection 
Reagent, Roche) was performed according to manufacturer´s protocol. For the DNA titration 
experiments, different amounts of DNA were used to form the transfection complex.   
 
3.3.4 Generation of Stably Transfected PAE-Cells by Retroviral Transduction 
HEK293 Ampho (5 x 106) cells were plated in 10-cm cell culture dishes and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma) supplemented with 10% fetal bovine serum 
(FBS). Cells were transfected with 10 µg pLib LN VEGFR-2 plasmid and 10 µg pVSV-G plasmid 
by Ca3(PO4)2 precipitation. Cells were then transferred to an S2 laboratory. Medium was replaced 
5 h later with 20 ml of fresh DMEM. Target PAE cells were seeded in 10-cm cell culture dishes in 
Ham’s F12 medium (Bioconcept) containing 10% FBS. After 24 h, the supernatant of the 
transfected HEK293 Ampho cells was filtered through a 45 µm-nitroacetate filter and added to the 
PAE cells. To increase the efficiency of infection, polybrene (Hexadimethrine bromide, Sigma 
H9268) was added to a final concentration of 4 µg/ml. Fresh DMEM was added to the HEK293 
Ampho cells. Infection of PAE cells was repeated the next day. After 48 h, PAE cells were split 1/6 
and selected with 1 mg/ml G418. Selection medium was added every 3 days. After 2 weeks, cells 
were checked for expression. 
 
3.3.5 VEGF Receptor Activation 
HEK293 (5 x 105) cells were plated into 6-cm cell culture dishes, grown for 24 h in DMEM 
with 10% FBS, and transfected with Ca3(PO4)2 precipitation. At 30 h after transfection, cells were 
starved overnight in DMEM supplemented with 1% BSA. Transfected cells were stimulated with 
1.5 nM VEGF-A165 for 10 min at 37°C. Cells were rinsed once with ice-cold PBS followed by lysis 
in 200 µl lysis buffer (50 mM Tris, pH 7.5; 100 mM NaCl; and 0.5% w/v Triton X-100) containing 
protease inhibitor cocktail (Roche), phosphatase inhibitors (200 µM Na3VO4, 10 mM NaF, 10 mM 
sodium pyrophosphate, 30 mM paranitrophenylphosphate, 80 mM glycerophosphate, and 20 µM 
phenylarsine oxide), and 10% glycerol. Cell lysates were boiled in Lämmli buffer (20 mM Tris, 
pH 6.8; 5% SDS; 10% mercaptoethanol; and 0.02% bromophenol blue) and resolved on 8% SDS 
gels, blotted to PVDF membranes, and immunodecorated with phospho-specific antibody pY1175 
or VEGFR-2 specific antibody (Cell Signaling). All experiments were performed in triplicates and 
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immunoblots were quantified by densitometric scanning using the ImageQuant TL software 
(Molecular Dynamics, GE Healthcare). 
 
3.3.6 Immunocytochemistry  
HEK293, COS-1, or stably transfected PAE cells were grown on glass coverslips to a density 
of approximately 60%. HEK293 and COS-1 cells were transfected with the VEGFR-2 constructs. 
Cells were fixed with 3.7% formaldehyde in PBS for 10 min at 37 °C followed by extensive 
washing with PBS. Cells were permeabilized with 1% NP40 in PBS for 10 min at RT. The first 
antibody diluted in PBS was added to the cells for 2 h at room temperature followed by incubation 
with fluorescence-labeled secondary antibody for 1 h. Samples were washed with PBS before they 
were embedded in gelvatol (15% gelvatol, 33% glycerol, 0.1% sodium azide). Images were 
acquired on an Olympus IX81 epifluorescence microscope and processed using spectral unmixing 
and 3D deconvolution software (Olympus Cell^R). 
 
3.3.7 Sprouting of BAECs 
BAECs were cultured in DMEM supplemented with 10% normal calf serum (NCS). A total 
of 500 cells were used to generate one hanging drop. Hanging drops were incubated upside down at 
37 °C. After 24 h, spheroids were collected and pooled by centrifugation (100 rcf, 3 min). On ice, 
8 volumes of collagen I stock (BD Biosciences) were mixed with one volume of 10 x PBS and 
0.023 volumes of 1 N NaOH. Basal medium was added up to ten volumes. Spheroids were 
resuspended in basal growth medium with inclusion of DARPin (100 nM) and mixed 1:1 with the 
collagen-containing medium. Spheroids were transferred to a prewarmed 24-well plate (500 µl, 
20 spheroids per well) and polymerization was induced by incubation at 37 °C for 2 h. Gels were 
overlaid with 500 µl of normal growth medium supplemented with 1% FCS with VEGF-A165 
(1.5 nM final concentration) and incubated for 24 h. Spheroids were fixed with 3.7% formaldehyde 
at 37 °C o/n. After washing with PBS spheroids were stained with phalloidin-rhodamin (Cell 
Signaling) and imaged. In the spheroid assay the length and number of sprouts was determined 
using the Image J software (NIH). Sprouts from two independent experiments were statistically 
analysed for each condition. 
Live-cell imaging was performed by incubating a spheroid in a Ludin-chamber at 37 °C during 
24 h.   
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3.3.8 Cloning of Expression Plasmids 
Mammalian expression plasmids for VEGFR-2-D7 (aa 663-764) and VEGFR-2-D6-7 
(aa 549-764) production were generated using PCR-subcloning (Geiser et al., 2001). Ig-homology 
domain 7 was PCR-amplified from pcDNA3-VEGFR-2-D7-GCN4 using the forward primer 
5’- ATGGAGAGCAAGGTGCTGC-3’ and the reverse primer 
5’- GTGATGCTGGAAGTAGAGGTTCTCCAAGTTCGTCTTTTCCTGGGC -3’. Ig-homology 
domains 6-7 were amplified from pcDNA3-VEGFR-2-D1-7 using the forward primer 
5’- CGCCTCTGTGGGTTTGCCTAGGGGTCCTGAAATTACTTTGC -3’ and the reverse primer 
5’- GTGATGCTGGAAGTAGAGGTTCTCCAAGTTCGTCTTTTCCTGGGC -3’. The 
PCR-products were then subcloned back into the templates used for the amplification reaction, 
thereby deleting Ig-homology domains 1-5 or the sequence coding for a GCN4-zipper. 
VEGFR-2-D1-7 (residue 1-764) was cloned into the pFASTBAC plasmid (Invitrogen) for 
expression in Sf21 cells as described (Brozzo et al., 2011). 
 
3.3.9 Production and Purification of Recombinant Proteins 
VEGFR-2-ECD was produced and purified as described (Brozzo et al., 2011). Briefly, Sf21 
cells, maintained in serum-free Insect-Express (Lonza) media at 27 °C, were used to produce 
recombinant virus. When the cells reached a density of 106 cells/ml, they were infected with 
recombinant baculovirus at high multiplicity. Three days after infection, the supernatant was 
harvested by centrifugation at 900 g, concentrated and dialyzed against 20 mM sodium-phosphate 
buffer pH 7.4 and 500 mM NaCl. The conditioned medium was loaded onto a Ni2+-NTA agarose 
column (GE Healthcare). The His6-tagged protein was eluted with a gradient from 40-500 mM 
imidazole and further purified by gel filtration on a Superdex 200HR 10/30 column 
(GE Healthcare) equilibrated with 25 mM HEPES pH 7.5 containing 150 mM NaCl. 
VEGFR-2-D7 and VEGFR-2-D6-7 were produced in transiently transfected HEK293T cells 
as described (Aricescu et al, 2006 #139). When the cells reached ~90% confluency, the medium 
was changed from DMEM containing 10% fetal bovine serum to DMEM containing 0.5% fetal 
bovine serum. The preincubated DNA-polyethylenimine complex (at a 1:1.5 ratio) diluted in 
serum-free DMEM was added to the cells. Three days after transfection the medium was harvested, 
cleared by centrifugation, and concentrated. The His6-tagged proteins were purified by IMAC as 
described above. The buffer was exchanged to 25 mM HEPES pH 7.5, 150 mM NaCl using 
centrifugal protein concentrators (Sartorius Stedim Biotech). 
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3.3.10 Size Exclusion Chromatography coupled Multi-Angle Light Scattering (SEC-MALS) 
The SEC-MALS experiments were conducted on an Agilent 1100 HPLC-system (Agilent 
Technologies) with an analytical-grade Superdex 200HR 10/30 column (GE Healthcare) coupled to 
the Wyatt miniDAWN Tristar (Wyatt Technologies). The system was equilibrated in 25 mM 
HEPES pH 7.5, 150 mM NaCl at 20°C prior to the experiments. For each run around 100 µg of 
VEGFR-2-ECD alone, VEGF-A121 alone, VEGFR-2-ECD/VEGF-A121 complex, 
VEGFR-2-ECD/6C8/VEGF-A121 complex, and VEGFR-2-ECD/6G9/VEGF-A121 were loaded onto 
the SEC-column. The elution profiles were recorded as UV-absorbance at 280 nm and as the 
intensity of Rayleigh scattering at three different angles. In the case of 
VEGFR-2-ECD/6C8/VEGF-A121 and VEGFR-2-ECD/6G9/VEGF-A121, VEGFR-2-ECD was 
mixed with the inhibitor at a 1:3 molar ratio and incubated for 60 min at 4 °C. VEGF-A121 was 
added to the receptor at a molar ratio of 1:1.1 (receptor : ligand). The ASTRATM software (Wyatt 
Technologies) was used to calculate the weight average Molecular masses (Mw).  
 
3.3.11 Ribosome Display 
Ribosome display was performed by Molecular Partners AG, Schlieren, as described in 
(Zahnd et al., 2007) and (Binz et al., 2004). 
 
3.3.12 Epitope-mapping ELISA 
Epitope-mapping ELISA was performed by Molecular Partners AG, Schlieren, using Surface 
Plasmon Resonance (ProteOn XPR36, Biorad, Switzerland) (Reference: Dr. Kaspar Binz, 
Molecular Partners AG, Zürich-Schlieren, Switzerland). 
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3.4 Results 
3.4.1 Role of membrane-proximal Ig-homology domains 4 and 7 in receptor activation 
In the crystal structure of the c-Kit receptor, two amino acids Arg381 and Glu386 in the 
EF loop of D4 were identified that form salt bridges mediating homotypic interaction of receptor 
monomers. Sequence alignment showed that this dimerization motif is conserved among several 
type III and type V RTKs and is also found in D7 of VEGFR-2. Based on this alignment, we 
generated a series of VEGFR-2 D7 mutants where parts of or the entire loop containing this 
dimerization motif were mutated (Fig. 3-1). 
 
 
 
Figure 3-1: Schematic representation of the βE-βF loop in VEGFR-2 D7 and sequences of generated 
mutants. 
Mutated amino acids are indicated in red, wild type amino acids in blue.  
 
  
VEGFR-2 WT:!
VEGFR-2 xD7EF:!
VEGFR-2 D731A:!
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We transiently expressed these mutant receptors in HEK293 cells and generated stably 
expressing retrovirus-infected PAE cell lines. To create amphitropic retroviruses, VEGFR-2 
constructs were cloned into the pLIB retroviral expression vector providing a ψ+ packaging signal. 
The packaging cell line HEK293 Ampho expressing the viral gag, pol, and env genes, was 
transfected with the retroviral expression vector. The viral genomic transcript containing the target 
gene and a selectable neomycin resistance marker was packaged into infectious virus and 
subsequently used to infect PAE cells. 
Transiently or stably transfected cells were starved, stimulated with VEGF-A165 for 10 min 
and lysed. Ligand-induced VEGFR-2 activation was determined by western blotting with 
anti-phosphotyrosine 1175 and anti-VEGFR-2 antibodies. All mutants except mutant xD7EF, 
whose phosphorylation was completely blocked, retained some autophosphorylation activity both in 
stable (Fig. 3-2) and in transiently transfected cells (Suppl. Fig. 3-12). The ratio of phosphorylation 
normalized to total VEGFR-2 compared to wt (wt value set to 1.0) was: RRRK: 0.51 ±0.10; mutant 
RRR: 0.65 ±0.36; mutant R: 0.43 ±0.18; mutant EDE: 0.44 ±0.26; mutant ED: 0.78 ±0.34; mutant 
D: 0.68 ±0.11; mutant xD7EF: 0.00 ±0.08. 
 
Figure 3-2: The conserved dimerization motif in D7 is crucial for ligand-induced activation of 
VEGFR-2. 
Ligand-induced activation of VEGFR-2 is compromised by mutation of the EF-loop in D7. PAE cells stably 
expressing the indicated VEGFR-2 mutants were generated by retroviral transduction. Cells were stimulated 
with 1.5 nM VEGF-A165 for 10 min at 37°C. Cell lysates were analysed on Western blots with 
phospho-specific antibody pY1175 and anti-VEGFR-2 antibody.  
WB: anti-pY1175 
WB: anti-VEGFR-2 
+ - - + 
VEGF-A165 
wt     D731A R726A xD7EF 
+ - + - 
WB: anti-pY1175 
WB: anti-VEGFR-2 
+ - - + 
VEGF-A165 
RRR     EDE ED RRRK 
+ - + - 
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Therefore, the homotypic interactions that take place between D7 play an essential role in 
receptor activation. These data show that homotypic interaction between D7 revealed in the 
published VEGFR-2 D7 structure (Yang et al., 2010) is required for receptor activation. Point 
mutation of these sites gave rise to partially defective receptors presumably due to compensatory 
interactions mediated by other charged amino acids in the EF loop. Mutation of all charged amino 
acids in the EF loop completely blocked receptor activation in both transiently and stably 
transfected cell lines and thus showed that D7 interaction plays an essential role in receptor 
activation. 
For D4, which seems to be involved in receptor dimerization (Ruch et al., 2007) but has not 
yet been as extensively studied as D7, we generated mutants where the entire domain was either 
replaced by D5 of VEGFR-1 (3/5) or deleted (Delta 4). Mutants were transiently or stably 
transfected into HEK293 and PAE cells respectively. Both mutants were completely inactive in the 
phosphorylation assay (Fig. 3-3 and Suppl. Figures 3-13 and 3-14). The ratio of phosphorylation 
normalized to total VEGFR-2 compared to wt (wt value set to 1.0) was: 3/5: 0.02±0.03; mutant Δ4: 
0.00±0.12, mutant Δ5 0.93. This shows that D4 is required for correctly positioning receptor 
monomers in active dimers. In addition to D7, D4 plays a crucial role in VEGFR-2 activation.  
 
 
 
Figure 3-3: D4 is essential for ligand-induced VEGFR-2 activation. 
Ligand-induced activation of VEGFR-2 is compromised by mutation of D4. PAE cells stably expressing 
VEGFR-2 3/5 or VEGFR-2 Delta 4 were stimulated with 1.5 nM VEGF-A165 for 10 min at 37 °C. Cell lysates 
were analysed on Western blots with phospho-specific antibody pY1175 and anti-VEGFR-2 antibody. 
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3.4.2 Isolation and characterization of Ig-homology domain-specific DARPins 
To test the possibility whether VEGFR-2 activation can be blocked with reagents specifically 
binding to D4 or D7, we selected Designed Ankyrin Repeat Proteins (DARPins, (Binz et al., 2004)) 
binding to single Ig homology domains of VEGFR-2 ECD. Ribosome display was employed to 
select binders specific for the ECD of VEGFR-2. My colleague Edward Stuttfeld cloned the 
expression plasmids, expressed and purified all proteins used for ribosome display. The selected 
DARPins were then verified on recombinant VEGFR-2 ECD protein. A total of 18 DARPins was 
isolated and their affinities determined by surface plasmon resonance (confidential data, Molecular 
Partners AG, Schlieren). All DARPins bound the receptor with high affinity with Kds below 10 
nM. To determine the specificity of each DARPin, an ELISA with distinct ECD proteins 
encompassing various Ig homology domains was performed. Proteins used were: ECD D1-7, D7, 
D2-3 and D2-4. DARPin 6G9 bound to D1-7, D2-3, and D2-4. DARPin 6C8 was shown to be 
specific for D1-7 and D2-4.  DARPin 7H4 bound to D1-7 and D7 (Fig. 3-4). In conclusion, 
DARPin 6G9 is specific for D2-3, DARPin 6C8 for D4, and DARPin 7H4 for D7.   
 
 
	
  
 
Figure 3-4: DARPin specificity for VEGFR-2. 
Specificity of DARPins 3C8, 4E7, 6C8, 6G9, and 7H4 against VEGFR-2 ECD was determined by ELISA. 
Proteins used were: D1-7, D7, D2-3, and D2-4. BG: background signal. 
Figure and data in collaboration with Molecular Partners AG, Schlieren. 
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To verify that these DARPins recognized VEGFR-2 also on cells, we analyzed receptor 
binding by fluorescence microscopy using a series of distinct receptor-expressing cells. HEK293 
cells expressing wt or mutant VEGFR-2 (VEGFR-2 Delta4) were fixed, permeabilized and 
incubated with DARPins. DARPins were then labelled with anti-His and fluorescently labelled 
anti-mouse antibodies. DARPins 6C8 and 6G9 both recognized the receptor on the cell surface as 
well as in intracellular vesicles following ligand stimulation (Fig. 3-5). As expected, 6G9 bound 
both wt as well as D4 deleted VEGFR-2. In agreement with the epitope-mapping ELISA, 6C8 only 
recognized wt VEGFR-2, but not D4 deleted receptor. Control stainings can be found in 
suppl. Fig. 3-15. 
 
 
 
Figure 3-5: DARPin 6C8 binds to D4 and DARPin 6G9 to D2-3. 
HEK293 cells were transiently transfected with VEGFR-2 wt (top) or Δ4 mutant (bottom), fixed and stained 
with DARPin 6G9 or 6C8, anti-His, and anti-mouse Cy3 antibodies (red). As a control (left panels), cells 
were stained with a commercially available anti-VEGFR-2 antibody and an Alexa488 labeled secondary 
antibody (green). Figure K. Ballmer-Hofer. 
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3.4.3 Effect of DARPins on ligand-mediated receptor dimerization 
Next, we analysed whether inhibitors of D4 affected ligand-mediated receptor dimerization. 
Multi-angle light scattering (MALS) experiments were carried out by my colleague Edward 
Stuttfeld. We determined receptor dimerization using recombinant receptor ECD proteins incubated 
with ligand in the presence or absence of DARPins and analyzed by MALS. DARPin 6G9 specific 
for D2-3 completely blocked receptor dimerization (Fig. 3-6). 
Incubation of VEGFR-2-ECD with the DARPin 6G9 showed three peaks with calculated Mws 
of 110.6, 28.7, and 18.7 kDa, corresponding to one VEGFR-2-ECD molecule in complex with the 
DARPin 6G9, unbound VEGF-A121, and excess of DARPin 6G9, respectively. On the other hand, 
the inhibitory DARPin 6C8 which is specific for D4 resulted in two peaks with apparent Mw of 
217.2 and 20.4 kDa. While the peak with an apparent Mw of 20.4 kDa represents the excess of 
DARPin 6C8, the peak with the calculated Mw of 217.2 kDa consists of VEGFR-2-ECD bound to 
the DARPin as well as the VEGF-A121. This is supported by the fact that the elution volume of 
VEGFR-2-ECD/6C8/VEGF-A121 shifts to a lower value compared to VEGFR-2-ECD/VEGF-A121 
alone, suggesting that a bigger complex is present. 
However, it is arguable whether the complex contains two DARPin molecules or only one 
DARPin molecule. The addition of the theoretical Mws of the individual components gives values 
of 235 kDa for a 2:2:2 (VEGFR-2/VEGF/DARPin) complex and 217 kDa for a 2:2:1 complex, 
indicating that the latter is present. Nonetheless, these results suggest, that DARPin 6G9 inhibits 
VEGFR-2 signaling by blocking the ligand-binding site, whereas DARPin 6C8 affects the 
VEGFR-2 signaling in an “allosteric” like mechanism without preventing ligand-binding.  
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Figure 3-6: DARPin 6C8 does not interfere with dimerization of VEGFR-2 ECD whereas DARPin 6G9 
prevents dimerization in the presence of VEGF. 
Receptor ECD proteins were incubated with ligand in the presence of DARPin 6G9 (top panel) or 6C8 
(bottom panel) an analyzed by MALS. After the MALS run, proteins were analysed by Western blot to 
confirm their dimerization status. Figure E. Stuttfeld. 
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3.4.4 Functional characterization of receptor-inhibitory DARPins 
All 18 DARPins specifically binding to the ECD of VEGFR-2 were now tested for their 
ability to inhibit VEGFR-2 activation (suppl. Fig. 3-16). PAE cells expressing VEGFR-2 were 
incubated with DARPins for 30 min before stimulation with VEGF-A165 (Fig. 3-7 top). DARPin 
6G9 completely blocked receptor kinase activation. Most interestingly, the D4-specific DARPin 
6C8 also reduced ligand-induced receptor phosphorylation. The two DARPins bind to different Ig 
homology domains and both inhibit activation. Furthermore, DARPin 6G9 completely inhibited 
VEGF-A165 induced PLC-γ1 phosphorylation whereas 6C8 led to a decrease of PLC-γ1 
phosphorylation in PAE-VEGFR-2 cells (Fig. 3-7 bottom). 
 
 
Figure 3-7: DARPins 6G9 and 6C8 inhibit VEGFR-2 activation and downstream signaling. 
PAE-VEGFR-2 cells were incubated with 100 nM DARPins for 30 min at 37°C and stimulated with 1.5 nM 
VEGF-A165 for 10 min at 37°C. Cell lysates were analysed on Western blots with phospho-specific antibody 
pY1175, anti-VEGFR-2 antibody (top) and phospho-PLG-γ1, anti-PLC-γ1 antibody (bottom). 
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Immunofluorescence of VEGFR-2 expressing PAE cells incubated with DARPins 30 min 
prior to stimulation showed that the receptor was retained on the cell surface (Fig. 3-8), while 
receptor was rapidly internalized in the absence of DARPins following ligand stimulation. 
Therefore both DARPin 6C8 and 6G9 blocked internalization of the receptor. 
 
 
 
Figure 3-8: DARPins 6G9 and 6C8 inhibit VEGFR-2 internalization after stimulation. 
PAE-VEGFR-2 cells were incubated with DARPin 6G9 or 6C8 30 min prior to ligand stimulation. Cells were 
fixed before stimulation (left panel) or 30 minutes after stimulation (three right panels). Membrane-bound 
and internalized VEGFR-2 was detected with an anti-VEGFR-2 antibody.  
Figure K. Ballmer-Hofer.     
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To analyze the effect of the inhibitory DARPins on endothelial cell sprouting, we embedded 
BAEC spheroids in collagen gels containing 100 nM of DARPins. The incubation with DARPin 
6C8 led to significantly decreased relative sprouting compared to control (Fig. 3-9). The effect was 
more drastic than with the 6G9 DARPin. Experiment was repeated and showed similar results. 
 
 
 
 
Figure 3-9: DARPins 6G9 and 6C8 inhibit sprouting of BAECs in the EC-spheroid assay. 
(A) BAECs were embedded in collagen gels containing 100 nM DARPins. Collagen gels were overlaid with 
1.5 nM VEGF-A165 and sprouting was analysed after 24 h. Cells were fixed and visualized with a 
TRITC-labeled anti-phalloidin antibody. (B) Relative sprouting (number x average length of sprouts), 
*p < 0.05, ****p < 0.0001. Error bars represent ± SEM. 
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We further monitored endothelial cell sprouting by live-cell imaging. Spheroids stimulated 
with VEGF-A165 were incubated in the presence or absence of DARPin 6C8 and monitored for 
16 h. Representative pictures are presented in Fig. 3-10 (without DARPin) and Fig. 3-11 (with 
DARPin 6C8) and confirmed inhibition of BAEC sprouting by DARPin 6C8.  
 
 
	
  
Figure 3-10: Endothelial cell sprouting over time. 
Sprouting of BAEC spheroids was monitored over 16 h after VEGF-A165 incubation. Figures show six 
representative time points (A: 0 h, B: 3.2 h, C: 6.4 h, D: 9.6 h, E: 12.8 h, F: 16 h). Arrowheads indicate 
emerging and growing sprouts. 
A B C 
D E 
0 h 3.2 h 6.4 h 
9.6 h 12.8 h 
Time line 
F 
16 h 200 µm 
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Figure 3-11: Inhibition of endothelial cell sprouting by DARPin 6C8. 
Sprouting of BAEC spheroids was monitored over 16 h after VEGF-A165 incubation in the presence of 
DARPin 6C8. Figures show six representative time points (A: 0 h, B: 3.2 h, C: 6.4 h, D: 9.6 h, E: 12.8 h, 
F: 16 h). 
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3.5 Discussion 
We demonstrated that homotypic interactions between D7 previously indicated in the 
VEGFR-2 D7 structure (Yang et al., 2010) are required for receptor activation. These interactions 
are mediated by conserved paired amino acids in the loop linking the βE and βF strands. Point 
mutation of these residues gave rise to only partially defective receptors presumably due to 
compensatory interactions mediated by other charged amino acids in the loop. Mutation of all 
charged amino acids in the EF loop completely blocked receptor activation in both transiently and 
stably transfected cell lines and thus confirmed that D7 interactions play an essential role in 
receptor activation. 
Our results are partially contradictory to the recently published functional data (Yang 
et al., 2010). Yang et al showed that also point mutations in the EF loop are sufficient to strongly 
compromise the ligand-induced activation of VEGFR-2. Our data show that receptor kinase 
inhibition is only observed when the entire loop was mutated. There are various explanations for 
this observation: the cell line used by Yang et al. for the generation of stable lines are NIH-3T3 
cells, a non-endothelial fibroblast cell line usually not involved in angiogenesis. We believe that our 
PAE cells are more representative of endothelial cells and thus better suited for functional analysis. 
In addition, some of the receptor mutants employed in the study were chimeric receptors composed 
of the VEGFR-2 ECD linked to the TM and cytoplasmic domain of PDGFR. The authors claim that 
this was done to overcome the relatively weak kinase activity of VEGFR-2. Again, such artificially 
engineered receptors might be problematic for mimicking the actual in vivo situation in developing 
vessels.   
The EM structure of the ECD of VEGFR-2 published by our laboratory revealed that in 
addition to D7, D4 also seems to be involved in homotypic interactions between ligand-bound 
receptor dimers (Ruch et al., 2007). In agreement with functional data published earlier on 
VEGFR-1 (Barleon et al., 1997), D4 would be involved in stabilizing receptor dimers. To 
investigate the role of D4 in receptor activation and in intracellular signaling, we constructed 
VEGFR-2 mutants where D4 was either deleted (Δ4) or replaced by D5 of VEGFR-1 (mutant 3/5), 
a domain which until now has not been shown to play a specific role in receptor activation. We 
performed phosphorylation assays with HEK293 cells transiently transfected with the D4 mutants 
and further generated stable PAE cells expressing this mutant. Compared to transiently transfected 
cells, stably transfected cell lines expressed physiologically relevant receptor levels. In contrast to 
the wt VEGFR-2, D4 mutants were not phosphorylated after VEGF-A stimulation showing that D4 
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is indeed indispensable for receptor activation. By manual sequence alignment, Yang et al. 
identified a conserved sequence motif of “D/E-x-G” amino acids in D4 similar to the dimerization 
motif in D4 of c-Kit and PDGFR. In their study, mutations of the conserved D392 to an A did not 
lead to receptor inactivation, neither did the mutations of residues E387 and R391 which they 
claimed to be the non-conserved pair of amino acids with opposite charges responsible for the 
generation of salt bridges in D4 (similar to R726 and D731 in D7). We propose that similar to the 
D7 mutants, compensatory interactions are mediated by other charged amino acids in the loop, such 
as for example E390. Another possibility could be that D4 interactions are mediated through a 
different interface, as proposed earlier (Yang et al., 2010). This seems highly probable since the 
sequence identity between D4 of PDGFR-α and VEGFR-2 is only 20% which makes it rather 
difficult to draw conclusions based on sequence alignment. 
We also demonstrated that activation of VEGFR-2 requires specific positioning of 
intracellular kinase domains relative to each other following conformational changes (Dell'Era 
Dosch et al., 2009). Dimerization is hence necessary but not sufficient for receptor activation and 
downstream signaling, and requires exact positioning of the kinase domains relative to each other in 
receptor dimers. We now show that this orientation is mediated by the homotypic interactions 
between the membrane-proximal Ig-homology domains in the ECD in the full length receptor. As 
proposed for the c-Kit receptor (D4) (Lemmon and Ferguson, 2007), we suggest that the weak 
interactions between ECD domains (D4 and D7 for VEGFR-2) are important for proper alignment 
of receptor monomers. We assume that the specific orientation resulting from ECD mediated 
dimerization through the binding of the ligand leads to a conformational reorganization of the 
juxtamembrane domain and intracellular kinase domain and subsequent kinase activation.  
In this study we provide functional evidence for the findings described in our EM structure of 
the VEGFR-2 ECD (Ruch et al., 2007). We demonstrate the importance of ECD Ig-homology 
domains D4 and D7 in VEGFR-2 activation. Both domains are required for mediating weak 
interactions between receptor dimers that are essential for receptor activation.  
In conclusion, homotypic contacts in the VEGFR-2 ECD seem to be ideal targets for 
therapeutic intervention in the treatment of diseases in which pathological RTK activation is 
observed. In a next step, we therefore developed specific binders for Ig-homology domains D4 and 
D7 of the VEGFR-2 ECD. The advantage of such VEGFR-2 inhibitors is that, in contrast to other 
less specific angiogenesis inhibitors, they specifically bind to the receptors and therefore interfere 
only with distinct signaling pathways. Since VEGF-A binds in an overlapping pattern to several 
VEGFRs, its inhibition interferes with a multitude of pathways (lymphangiogenesis). The clinically 
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most advanced VEGFR-2 inhibitor so far is Ramucirumab (IMC-1121) (Spratlin, 2011), a chimeric 
antibody against the ligand-binding domain of VEGFR-2. In early clinical trials many patients 
developed severe side-effects due to the chimeric antibodies, IMC-1121 was therefore fully 
humanized and is now being tested in several phase III clinical trials 
http://clinicaltrials.gov/ct2/results?term=ramucirumab. However, the disadvantage of inhibitors 
against ligand-binding domains is that they have to compete with the ligand and are less efficient at 
high ligand concentrations.  
We screened DARPin libraries against the entire ECD of VEGFR-2 and identified a number 
of inhibitors against the ligand-binding domain of VEGFR-2. As expected, these DARPins 
completely abolished ligand-induced VEGFR-2 activation and were a very good positive control for 
our experiments. In addition, and even more interestingly, we identified the 6C8 DARPin that binds 
specifically to D4 of the ECD. Incubation of PAE cells with the inhibitor prior to stimulation led to 
decreased receptor activation. Downstream signaling to PLC-γ was also compromised and sprouting 
in BAE cells was significantly weaker. We have thus found a potent inhibitor of VEGFR-2 
activation which has a different inhibition mechanism than inhibitors that interact with the 
ligand-binding domain. 
To further characterize the mechanism of inhibition, we investigated the dimerization status 
of ECD-proteins incubated with DARPin 6C8. The DARPin still enabled ligand binding. More 
importantly, 6C8 did not interfere with receptor dimerization. This confirms the findings that the 
homotypic interactions in the ECD are dispensable for receptor dimerization as shown for RTKs 
such as Kit (Yuzawa et al., 2007), PDGFR (Yang et al., 2008), and VEGFR (Yang et al., 2010). In 
addition, the receptor was still dimerized when the inhibitor was present and dimerization is thus 
not sufficient for activation of the VEGFR-2.  
In summary, we have identified a high-affinity inhibitor specific for D4 of VEGFR-2 that has 
the advantage of binding specifically to VEGFR-2 and functions independently from ligand 
concentration. Our inhibitor suppresses VEGF-A mediated receptor activation and downstream 
signaling by interfering with the correct 3 dimensional organization of receptor monomers in active 
dimers. The only dimerization blocking inhibitor in clinical trials so far is pertuzumab, an antibody 
against ErbB2 (Franklin et al., 2004) (Badache and Hynes, 2004). Pertuzumab blocks ErbB2 
heterodimerization with other members of the ErbB family. At the time of writing, Tvorogov et al. 
reported a mAb against D5 of VEGFR-3 which by inhibiting VEGFR-2/VEGFR-3 
heterodimerization suppresses signal transduction, migration, and sprouting of microvascular 
endothelial cells (Tvorogov et al., 2010). Furthermore, Kendrew et al. generated a human Ab in a 
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Xenomouse which binds to D4-7 of VEGFR-2 and suppresses VEGFR-2 activation (Kendrew et 
al., 2011). They speculate that the Ab interferes with receptor dimerization but could not decipher 
the mode of action. 
Potent and high-affinity inhibitors like the identified DARPin could in the future be employed 
in clinical applications such as tumor vasculature imaging. Furthermore, one could consider using it 
as an angiogenesis inhibitor in vivo. 
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3.6 Supplementary Information 
 
 
 
 
Figure 3-12: Schematic representation of VEGFR-2 mutants. 
Green spheres represent the Ig homology domains in the ECD of VEGFR-2. Shown are VEGFR-2 wt, 
VEGFR-2 Δ4, VEGFR-2 Δ5, VEGFR-2 3/5, and VEGFR-2 D7 mutants.  
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Figure 3-13: Ligand-induced activation of VEGFR-2 is compromised by mutation of D4 and D7. 
HEK293 cells were transiently transfected with the indicated VEGFR-2 mutants and stimulated with 1.5 nM 
VEGF-A165 for 10 min at 37°C. Cell lysates were analysed on Western blots with phospho-specific antibody 
pY1175 and anti-VEGFR-2 antibody. 
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Figure 3-14: Ligand-induced activation of VEGFR-2 is compromised by mutation of D4. 
We adjusted the expression level of the VEGFR-2 mutant constructs by titrating the amount of DNA used for 
transfection. HEK293 cells were transiently transfected with the indicated VEGFR-2 mutants. Amount of DNA 
used for transfection was varied to obtain a comparable expression level between the mutants. Amounts 
were 0.5 and 1 µg for the wt construct and 2, 1.5, 1.75 µg for Δ4. Cells were stimulated with 1.5 nM 
VEGF-A165 for 10 min at 37 °C. Cell lysates were analysed on Western blots with phospho-specific antibody 
pY1175 and anti-VEGFR-2 antibody. 
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Figure 3-15: Stainings of VEGFR-2 on cells with DARPins are specific. 
Control stainings were performed. DARPins and antibodies were used are indicated in white. HEK293 cells 
were transiently transfected with VEGFR-2 plasmids, fixed and stained with DARPin 6G9 or 6C8, anti-RGS 
His, and anti-mouse Cy3 antibodies (red). 
Figure K. Ballmer-Hofer.   
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Figure 3-16: DARPins 3C8, 6G9, and 6C8 inhibit VEGFR-2 activation. 
PAE-VEGFR-2 cells were incubated with 100 nM DARPins for 30 min at 37 °C and stimulated with 1.5 nM 
VEGF-A165 for 10 min at 37 °C. Cell lysates were analysed by Western blot with phospho-specific antibody 
pY1175 and anti-VEGFR-2 antibody.  
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Table 3-1: Primers used for cloning VEGFR-2 3/5 mutant. 
Construct	
   Orientation	
   5	
  –	
  3	
  sequence	
  
pcDNA5	
  FRT	
  VEGFR-­‐2	
  3/5	
   forward	
  
347	
  
5´GCA	
   CAT	
   TTG	
   TCA	
   GGG	
   TCC	
   ATG	
   AAA	
   AAC	
   CAG	
  
ACC	
  CGG	
  CTC	
  TCT	
  ACC	
  3´	
  
	
   reverse	
  
346	
  
5´GAT	
   TAG	
   AGA	
   TTT	
   CTC	
   ACC	
   AAT	
   CTG	
   GGG	
   TGG	
  
CAC	
  ATC	
  TGT	
  GAT	
  ATA	
  AAA	
  GC	
  3´	
  
 
 
 
Table 3-2: Primers used for cloning VEGFR-2 domain 7 mutants. 
The codons introducing the mutations are underlined. 
Construct	
   Orientation	
   5	
  –	
  3	
  sequence	
  
pcDNA5	
  FRT	
  VR2	
  R	
   forward	
   5´	
  CCG	
  GAA	
  CCT	
  CAC	
  TAT	
  CCG	
  CGC	
  AGT	
  GAG	
  GAA	
  GGA	
  
GGA	
  CGA	
  AGG	
  3´	
  
pcDNA5	
  FRT	
  VR2	
  D	
   forward	
   5´	
  AGT	
  GAG	
  GAA	
  GGA	
  GGC	
  CGA	
  AGG	
  CCT	
  CTA	
  CAC	
  CTG	
  
CC	
  3´	
  
pcDNA5	
  FRT	
  VR2	
  xD7EF	
   forward	
   5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  GCC	
  GCA	
  GTG	
  GCC	
  
TCA	
  GCC	
  GCC	
  GAA	
  GGC	
  CTC	
  TAC	
  ACC	
  TGC	
  CAG	
  3´	
  
pcDNA5	
  FRT	
  VR2	
  RRR	
   forward	
  
338	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  GCC	
  GCA	
  GTG	
  GCC	
  
AAG	
  GAG	
  GAC	
  GAA	
  GGC	
  CTC	
  TAC	
  ACC	
  TGC	
  CAG	
  3´	
  
pcDNA5	
  FRT	
  VR2	
  RRRK	
   forward	
  
339	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  GCC	
  GCA	
  GTG	
  GCC	
  
TCA	
  GAG	
  GAC	
  GAA	
  GGC	
  CTC	
  TAC	
  ACC	
  TGC	
  CAG	
  3´	
  
pcDNA5	
  FRT	
  VR2	
  ED	
   forward	
  
340	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  CGC	
  AGA	
  GTG	
  AGG	
  
AAG	
  GCC	
  GCC	
  GAA	
  GGC	
  CTC	
  TAC	
  ACC	
  TGC	
  CAG	
  3´	
  
pcDNA5	
  FRT	
  VR2	
  EDE	
   forward	
  
341	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  CGC	
  AGA	
  GTG	
  AGG	
  
AAG	
  GCC	
  GCC	
  GCC	
  GGC	
  CTC	
  TAC	
  ACC	
  TGC	
  CAG	
  3´	
  
Reverse	
   primer	
   (for	
   all	
  
above)	
  
reverse	
   5´ACA	
  GGG	
  ATT	
  GCT	
  CCA	
  ACG	
  TAG	
  3´	
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Table 3-3: Primers used for cloning pLIB constructs. 
The codons introducing the restriction sites or the mutations are underlined. 
Construct	
   Orientation	
   5	
  –	
  3	
  sequence	
  
pLIB	
  VEGFR-­‐2	
  wt	
   forward	
  (SalI	
  
restriction	
  site	
  
underlined)	
  
5´	
  GAT	
  CGT	
  CGA	
  CAT	
  GGA	
  GAG	
  CAA	
  GGT	
  GCT	
  
GCT	
  GGC	
  CG	
  3´	
  
	
   reverse	
  (NotI	
  
restriction	
  site	
  
underlined)	
  
5´	
  TAG	
  ACT	
  CGA	
  GCG	
  GCC	
  GCT	
  CAC	
  AGA	
  TCC	
  
TCT	
  TC	
  3´	
  
pLIB	
  VEGFR-­‐2	
  3/5	
  	
   forward/reverse	
  
as	
  first	
  entry	
  
	
  
pLIB	
  VEGFR-­‐2	
  K868M	
  	
   forward/reverse	
  
as	
  first	
  entry	
  
	
  
pLIB	
  VEGFR-­‐2	
  R	
  	
   forward/reverse	
  
as	
  first	
  entry	
  
	
  
pLIB	
  VEGFR-­‐2	
  D	
  	
   forward/reverse	
  
as	
  first	
  entry	
  
	
  
pLIB	
  VEGFR-­‐2	
  RD	
   forward/reverse	
  
as	
  first	
  entry	
  
	
  
pLIB	
  VEGFR-­‐2	
  RRR	
   forward	
  
338	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  GCC	
  GCA	
  
GTG	
   GCC	
   AAG	
   GAG	
   GAC	
   GAA	
   GGC	
   CTC	
   TAC	
  
ACC	
  TGC	
  CAG	
  3´	
  
	
  
pLIB	
  VEGFR-­‐2	
  RRRK	
   forward	
  
339	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  GCC	
  GCA	
  
GTG	
   GCC	
   TCA	
   GAG	
   GAC	
   GAA	
   GGC	
   CTC	
   TAC	
  
ACC	
  TGC	
  CAG	
  3´	
  
	
  
pLIB	
  VEGFR-­‐2	
  ED	
   forward	
  
340	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  CGC	
  AGA	
  
GTG	
   AGG	
   AAG	
   GCC	
   GCC	
   GAA	
   GGC	
   CTC	
   TAC	
  
ACC	
  TGC	
  CAG	
  3´	
  
pLIB	
  VEGFR-­‐2	
  EDE	
   forward	
  
341	
  
5´	
  GGG	
  AAC	
  CGG	
  AAC	
  CTC	
  ACT	
  ATC	
  CGC	
  AGA	
  
GTG	
   AGG	
   AAG	
   GCC	
   GCC	
   GCC	
   GGC	
   CTC	
   TAC	
  
ACC	
  TGC	
  CAG	
  3´	
  
Reverse	
   primer	
   (for	
   the	
   four	
  
constructs:	
  RR,	
  RRR,	
  ED,	
  EDE)	
  
reverse	
   5´	
  ACA	
  GGG	
  ATT	
  GCT	
  CCA	
  ACG	
  TAG	
  3´	
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4 Isolation of single chain variable fragment antibodies against Ig-homology 
domain 7 of the VEGFR-2 extracellular domain 
4.1 Introduction 
Monoclonal antibodies (mAbs) have proven to be effective therapeutic agents and are the 
major group of recombinant proteins currently used in the clinic (Reichert et al., 2005). Originally, 
mAbs were generated by fusing mouse lymphocytes and myeloma cells to create antibody-secreting 
murine hybridomas (Kohler et al., 1975).  However, murine antibodies present several 
disadvantages such as immunogenicity and lack of efficacy when used in humans (Tjandra 
et al., 1990). To circumvent these limitations, genetic engineering has been used to humanize the 
antibodies, replacing the murine antibody scaffold by human amino acid sequences (Riechmann 
et al., 1988). Recently, the generation of antibodies in living organisms has been extended by the 
use of genetically engineered antibody libraries. Diversity in the libraries is obtained by performing 
polymerase chain reaction (PCR) on V-germline genes with degenerated primers against the 
Complementarity Determining Region (CDR3) of the variable regions of immunoglobulins (Winter 
et al., 1994). Through the phage-display technology, antibodies against almost any antigen can be 
selected in vitro from such highly diverse libraries. Single chain variable fragments (scFvs) are 
expressed on the surface of a filamentous phage as fusion proteins with the phage minor coat 
protein (pIII). ScFvs with desired specificities are selected by repeated panning on the antigen of 
interest (Pini et al., 1998). ScFvs of interest are then further amplified by infection of bacterial 
strains with the selected phages. Determination of the scFv DNA sequence is possible and 
subsequent reformatting into fully human immunoglobulins can be achieved. The advantage of 
these antibodies for the use in human therapy over non-human, chimeric or humanized antibodies is 
their reduced immunogenicity.  
In this chapter I present the in vitro screening procedure of a scFv library against 
domain 7 (D7) of the VEGFR-2 extracellular domain (ECD). I performed the screen by 
phage display technology using the ETH-2 Gold antibody phage-display library (Silacci 
et al., 2005). A promising scFv candidate was amplified in E. coli and purified. The D7 binding 
scFv was further tested for specificity and the ability to inhibit VEGFR-2 on endothelial cells. 
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4.2 Materials and Methods 
4.2.1 Phage selection on immobilized antigen 
The ETH-2 Gold antibody phage-display library was kindly provided by Prof. Neri 
(ETH Zürich, Swizerland) (Silacci et al., 2005). A Maxisorp immunotube (Nunc GmbH, 
Wiesbaden, Germany) was coated with 50 µg/ml VEGFR-2 D7 (in 25 mM HEPES pH 7.5, 150 mM 
NaCl) o/n at RT using 4 ml of protein solution. The next day, the solution was discarded and the 
tube was rinsed three times with PBS. Blocking was performed on an orbital shaker for 2h with 
PBS containing 2.5% milk powder. The phage stock solution containing 5 x 1012 transducing units 
(tu) in PBS 2% milk powder was added to the immunotube. The tube was incubated at RT for 30 
min in an orbital shaker and for 1.5 h standing upright. The immunotube was now thoroughly rinsed 
10 times with PBS 0.1% Tween 20 and 10 times with PBS. In the following selection rounds, tubes 
were washed 20 times with each buffer. Bound phage was eluted by adding 1 ml 100 mM 
triethylamine (Sigma-Aldrich, Switzerland) to the tube and inverting at RT for 5 min. The eluate 
was added to an Eppendorf tube containing 500 µl 1 M Tris-HCl pH 7.4 to neutralize the 
triethylamine. The eluted phage was used to infect 10 ml of exponentially growing TG1 E. coli. 
TG1 at OD600 = 0.5 were infected for 30-40 min at 37 °C. Infected TG1 bacteria were centrifuged at 
3,300 g for 10 min. Pelleted bacteria were resuspended in 0.5 ml 2xTYE (yeast extract tryptone 
medium) and spread on two large 2xTYE plates (1.5% (w/v) agar) containing 100 µg/ml ampicillin 
and 1% glucose. Plates were incubated o/n at 30 °C. Three rounds of selection were performed. 
 
 
4.2.2 Enzyme linked Immunosorbent Assay 
Following three rounds of panning, individual bacterial colonies containing the phagemid 
were picked and grown in a 96-well plate in 2xTYE ampicillin 0.1% glucose for 3 h at 37 °C. The 
production of soluble scFv was induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG) 
(Fermentas) to a final concentration of 1 mM. The bacteria were further incubated for 16 h at 30 °C. 
The plate was centrifuged for 15 min at 1800 g and 50 µl bacterial supernatant from each well were 
used for enzyme linked immunosorbent assay (ELISA). A 96-well maxisorp plate (Nunc) was 
coated with VEGFR-2 D7 (5 µg/ml) o/n at 4 °C. Wells were rinsed three times with PBS and 
blocked with 350 µl PBS containing 5% BSA for 2 h on a shaker at RT. The bacterial supernatants 
were added and the ELISA plate was incubated for 1 h at RT on a shaker. Wells were thoroughly 
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rinsed three times with PBS-0.1% Tween 20 and three times with PBS before they were incubated 
with the anti-myc tag antibody (9B11 2040 Cell Signaling Technology) (1:1000 in PBS 2.5% 
BSA). After rinsing, an anti-mouse HRP antibody (Southern Biotech) (1:10.000 in PBS 2.5% BSA) 
was added for 1h at RT. When ELISA was performed directly with phages, an anti-phage antibody 
was used (M13 antiphage HRP-linked, ab50370, Abcam) (1:5000). Wells were washed again before 
100 µl of ready-to-use 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution (Thermo Scientific 
Pierce) were added to each well. The reaction was stopped after 10 min by adding 2 M H2SO4 and 
the OD450 was recorded. 
 
 
4.2.3 Expression and Purification of scFv 
A single colony of phagemid bearing E.coli TG1 was grown o/n at 37 °C in 2xTYE ampicillin 
1% glucose. The next day, 1 mL of TG1 was transferred to 1 L of 2xTYE ampicillin 0.1 % glucose 
and bacteria were grown for 3 h at 37 °C, 200 rpm. At an OD600 = 0.9, cells were induced by 
addition of IPTG to a final concentration of 1 mM. Cultures were then grown for another 16 h at 
30 °C, 200 rpm.  The following steps were all performed at 4 °C to avoid proteolytic digestion. 
Supernatants were centrifuged for 30 min at 4000 g and filtered through a 0.45 µm filter 
(Millipore). The supernatant was loaded onto a Protein A affinity column (Amersham Pharmacia 
Biotech). The column was washed first with Buffer A (100 mM NaCl, 0.1% Tween-20, 0.5 mM 
EDTA in PBS) then Buffer B (500 mM NaCl, 0.5 mM EDTA in PBS). The protein was eluted with 
100 mM triethylamine into tubes containing Tris HCl pH 6.8 for neutralization. The eluate was 
dialyzed overnight against PBS and concentrated. Proteins were stored at -80°C until further use. 
Proteins were resolved on 12% gels. 
 
 
4.2.4 Receptor kinase Inhibition Assay 
The inhibition assay was performed as described with the DARPins in section 3.2. 
Concentrations of scFv 3B1 were 0.03; 0.1; 0.3; 0.6; 1.2; and 2.5 µM. H9, a control scFv binding to 
VEGF-A and blocking its interaction with VEGFR-2 was used as a control for the inhibition of 
VEGFR-2 activation.  
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4.3 Results 
4.3.1 Production and purification of VEGFR-2 D7 
Purified VEGFR-2 ECD D7 was kindly provided by my colleague Edward Stuttfeld. In brief, 
D7 was expressed in transiently transfected HEK293T cells. D7 was enriched by immobilized metal 
ion affinity chromatography (IMAC) and further purified by size exclusion chromatography (SEC). 
Purified D7 was frozen at -80°C until further use. 
 
4.3.2 Phage display selection of scFvs against VEGFR-2 ECD D7 
We used the human fully synthetic ETH-2 Gold antibody phage-display library (Silacci et al., 
2005) for the selection of binders specific for D7 of VEGFR-2. D7 protein was coated to an 
immunotube o/n before phage library was added. Phages displaying scFvs that bound to D7 were 
retained while non-binding phages were removed by repetitive washing. D7 binding phages were 
then eluted and used to infect E. coli cultures in repeating selection and infection rounds. In this 
way, specific binders were amplified and enriched. An enrichment factor (EF) is calculated and 
represents the ratio of output vs. input phage titer (in transducing units, tu). Final enrichment was 
calculated from the EF ratio of consecutive rounds (EFn/EFn-1). In total, three rounds of phage 
selection were performed which led to a 50-fold enrichment between selection rounds two and three 
(Table 4-1). 
 
 
Table 4-1: Enrichment of binding phages during selection rounds. 
Round	
   Input	
  (tu)	
   Output	
  (tu)	
  
EF	
  
(output/input)	
  
Enrichment	
  
(EFn/EFn-­‐1)	
  
 
1	
   0.1x1013	
   6.5x104	
   6.5x10-­‐8	
   n/a	
  
2	
   1.6x1013	
   3.5x105	
   2.2x10-­‐8	
   0.34	
  
3	
   5.5x1013	
   6.0x107	
   1.1x10-­‐6	
   50	
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After three selection rounds, a total of 288 clones were picked to perform an initial enzyme 
linked immunosorbent assay (ELISA) for the identification of potential binder of VEGFR-2 D7. It 
has to be emphasized that we encountered unexpectedly low absorbance signals in the ELISA 
screen, probably due to low concentrations of scFvs in the 96-well plates. Binding of scFvs to both 
D7 and D1-7 was tested and, based on signal intensity in the ELISA screening, potential binders 
were selected as candidates for further rounds of verification. We focused on the two scFvs 3B1 and 
6G2 which gave the strongest signal. ScFv 1A1 was used as a non-binding control selected from the 
library. The three scFvs were produced in larger amounts and used in a secondary verification 
ELISA at higher scFv concentration. ScFvs 3B1 and 6G2 bound specifically to D7 and D1-7 
(Fig. 4-1). The 3E1 scFv showed unspecific binding to control protein and was therefore not 
considered for further detailed functional characterization. 
 
 
	
  
Figure 4-1: Binding specificities of anti-VEGFR-2 D7 scFv clones. 
ELISA of scFvs 3B1, 3E1, 6G2, and negative control scFv 1A1. Maxisorp plates were coated with 
VEGFR-2 D7, VEGFR-2 D1-7, or control protein. Phage supernatant containing the scFvs was added. ELISA 
was developed after addition of antibodies. 
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Myc-tag containing scFv 3B1 was expressed in 1L cultures and purified from the supernatant 
on a Protein A Sepharose column. We obtained a yield of 2.8 mg per liter. The purified scFv was 
then analysed by SDS-PAGE (Fig. 4-2). The major band was the 30 kDa monomer band indicating 
the expected molecular weight of a scFv. Bands with higher molecular weight represent oligomers. 
The Coomassie-blue stained gel also showed two lower bands not containing the myc-tag. 
 
 
	
  
 
Figure 4-2: Purification of anti-VEGFR-2 D7 scFv 3B1. 
(A) Elution profile on a Protein-A Sepharose column. Fractions were resolved on a 12% polyacrylamide gel. 
(B) Coomassie-blue staining. (C) Anti-myc immunoblot. 
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To determine the sequence of scFv 3B1, DNA was sequenced and showed the following 
amino acid sequences in the VH- and Vλ-segments (Table 4-2). 
 
 
Table 4-2: Amino-acid sequences in the randomized CDR3s of anti-VEGFR2 D7 scFvs. 
scFv	
   VH	
  (DP47)	
   Vλ	
  (DPL16)	
  
	
   95	
  96	
  97	
  98	
  99	
  100	
   91	
  92	
  93	
  94	
  95	
  96	
  
3B1	
   K	
  	
  	
  T	
  	
  	
  L	
  	
  	
  W	
  	
  	
  K	
  	
  	
  R	
   V	
  	
  	
  P	
  	
  	
  Y	
  	
  	
  D	
  	
  	
  P	
  	
  	
  A	
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4.3.3 Functional characterization of anti-VEGFR-2 D7 scFv 3B1 
 
Inhibition of VEGFR-2 activation by scFv 3B1 was now tested. The functional assay was 
similar to the one performed with the DARPin inhibitors (see section 3.4.4). PAE-VEGFR-2 cells 
were incubated with scFv prior to stimulation with 1.5 nM VEGF-A165. Western blot analysis was 
performed with cell lysates to determine receptor activation. Even at concentrations as high as 
2.5 µM, scFv 3B1 did not inhibit receptor activation (Fig. 4-4). The affinity of 3B1 to D7 will have 
to be determined in a competitive ELISA. Affinity maturation of the scFv could be performed to 
improve binding strength. 
 
 
	
  
 
Figure 4-3: ScFvs 3B1 in its current form does not inhibit VEGFR-2 activation. 
PAE-VEGFR-2 cells were incubated with increasing concentrations of scFv 3B1 (lane 1-5: 0.1; 0.3; 0.6; 1.2; 
and 2.5 µM) or H9, a control scFv binding to VEGF-A and blocking its interaction with VEGFR-2 (lane 8) at 
37 °C for 30 min. Cells were stimulated with 1.5 nM VEGF-A165 at 37 °C for 10 min. Lanes 6 and 7 represent 
unstimulated and stimulated cells, respectively. These cells were not incubated with any inhibitor. Cell lysates 
were analysed by Western blot with phospho-specific antibody pY1175 and anti-VEGFR-2 antibody protein. 
 
  
WB: anti-pY1175 
WB: anti-VEGFR-2 
3B1 
+ + 
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4.4 Discussion 
The fully human synthetic antibody library (ETH-2 Gold Library) (Silacci et al., 2005) was 
used to select scFvs against the D7 of the VEGFR-2 ECD. I identified scFv (3B1) using phage 
display which showed specific binding to the VEGFR-2 ECD D7. Preliminary experiments 
demonstrated the ability of 3B1 to bind VEGFR-2 on PAE cells stably expressing VEGFR-2 but 
will need to be confirmed. In its current form, the scFv did not inhibit ligand-induced activation of 
VEGFR-2 in PAE cells. Future experiments could therefore consist in further modifying the 
successful binder by for example reformatting it into an IgG antibody. This could lead to an 
increased chance of inhibiting receptor activation caused by the more bulky structure of the IgG 
while preserving the binding specificity to VEGFR-2 D7 identified in my screen. All scFvs will 
need further characterization including the determination of their affinity against D7 e.g. in a 
competitive ELISA assay or by Isothermal Titration Calorimetry. The scFvs may further be tested 
for inhibition of VEGFR-2 downstream signaling and sprouting assays already discussed in 
section 3.5 for the DARPins.  
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5 Novel functional germline variations in the vascular endothelial growth 
factor receptor 2 gene and their effect on gene expression and microvessel 
density in lung cancer 
 
The full manuscript can be found in appendix B.  
My contribution to this manuscript consisted in performing receptor activation assays with the 
different VEGFR-2 Single Nucleotide Polymorphisms (SNPs). HEK293 cells were transiently 
transfected with VEGFR-2 variants, stimulated with VEGF-A165, and lysed. Western blot analysis 
was performed with anti-pTyr1175 and anti-VEGFR-2 antibodies. Amount of VEGFR-2 
phosphorylation was quantified and statistically analysed (Fig. 2 in manuscript). Q472H showed a 
46% increase in VEGFR-2 phosphorylation after VEGF-A165 stimulation (p=0.035). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1: VEGFR-2 phosphorylation in HEK293 cells and effect of four non-synonymous variants. 
The y axis corresponds to the ratio of phosphorylated VEGFR-2 to total VEGFR-2. Values are normalized to 
basal phosphorylation levels of reference sequence KDR. “-” refers to basal phosphorylation levels and “+” 
refers to VEGF-A stimulation. Wt = reference sequence cDNA. The mean ± SEM of 3 experiments in 
triplicate is shown. 
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6 Monitoring Migration of Endothelial Cells on Micropatterned Biochips 
6.1 Abstract 
The vascular endothelial growth factor (VEGF) family consists of six polypeptides, 
VEGF-A, -B, -C, -D, -E, and PlGF. VEGFs exist as different isoforms which lead to distinct signal 
output. By specifically binding to type V receptor tyrosine kinases VEGFR-1, -2, and -3 and to 
coreceptors such as neuropilins, VEGFs regulate blood and lymphatic vessel development that play 
an important role in cancer development. However, the technologies to monitor these distinct 
outputs are currently limited. Here we present two methodologies to study VEGF-induced 
angiogenesis of endothelial cells on micropatterned coverslips that mimic the in vivo environment. 
Immunostaining demonstrates specific VEGF binding to coverslips patterned by “Molecular 
Assembly Patterning after Lift-Off” or by microfluidics. Immobilized VEGF was biologically 
active and endothelial cells expressing the receptor for the immobilized ligands migrated towards 
and adhered to the patterns. The chips present a robust and reproducible system that can be used to 
further characterize various cellular behaviors generated by multiple VEGF isoforms. 
6.2 Introduction 
Endothelial cell differentiation and sprouting is influenced by the extracellular matrix (ECM), 
neighboring cells and matrix-bound and soluble factors. Endothelial cells are capable of detecting 
slow increases in the local concentration of diffusible factors and are exposed to gradients of 
ECM-bound growth factors. Taken together, these factors generate the signals promoting cellular 
motility, proliferation, or differentiation and ultimately lead to the formation of new functional 
blood vessels.  
The most prominent growth factors in angiogenesis are the Vascular Endothelial Growth 
Factors (VEGFs). VEGFs interact with their target cells through receptor tyrosine kinases (RTKs), 
the VEGF receptors (VEGFR-1, -2 and -3). Ligand-induced activation of VEGFR-2 leads to 
intracellular signaling which subsequently mediates proliferation, migration, survival, and 
permeability of cells. VEGFs exist as many different isoforms which differ in their binding affinity 
to ECM molecules (Robinson and Stringer, 2001). Heparan sulfate glycosaminoglycans (HSPGs), 
components of the ECM, are highly sulfated glycosaminoglycan which have the function of storing 
and protecting growth factors such as VEGF (Folkman and Shing, 1992). VEGF-A165 binds to 
64 6. Monitoring migration of endothelial cells on micropatterned biochips 
 
 
 
HSPG via the heparin-binding domain located at the C-terminus whereas VEGF-A121 lacks this 
domain and is therefore soluble. Our laboratory has previously shown that different VEGF isoforms 
trigger distinct cellular responses (Cébe-Suarez et al., 2008;Cébe-Suarez et al., 2006a). The 
activation kinetics of VEGFR-2 are prolonged when the receptor is stimulated with matrix-bound 
VEGF compared to soluble VEGF. Furthermore, it has been recently demonstrated that the pattern 
of tyrosine phosphorylation is different when cells are stimulated with VEGF-A165 compared to 
VEGF-A121 and that the p38 MAPK downstream signaling pathway is enhanced (Chen et al., 2010). 
However, robust and reproducible techniques for the analysis of differences in cell behavior as a 
result of cells encountering soluble versus immobilized growth factors still need to be established. 
Existing technologies for protein immobilization include amine/carboxylic acid chemistry (Mann 
et al., 2001) (Stefonek-Puccinelli and Masters, 2008), thiol chemistry (Park et al., 2006), and 
biotin-avidin interactions (Gunawan et al., 2007). However, these approaches often lead to proteins 
bound in different conformations and orientation which may result in reduced protein activity. A 
few groups have used the elegant technique of indirectly coupling VEGF via heparin to obtain more 
uniform immobilization. Maynard et al. utilized a heparin-mimicking polymer to nanopattern 
VEGF (Christman et al., 2008) but did not test the surfaces for cell behavior in this study. Anderson 
et al. bound VEGF covalently as well as electrostatically to a heparin-modified surface (Anderson 
et al., 2009). Electrostatically and covalently immobilized VEGFs both led to similar levels of 
receptor phosphorylation. The drawback in this approach is that the VEGF was not micropatterned 
but present on the entire surface. 
Here, we present a study of micropatterned VEGF that can be used for cell studies. In a first 
approach, we made use of the natural affinity of VEGF-A165 to heparin for the binding of VEGF to 
a patterned surface. This strategy assured the correct positioning and orientation of the growth 
factor on the surface. For this, we combined the two techniques of micropatterning and indirect 
coupling via heparin for the site-selective anchoring of VEGF-A165. The surfaces allowed us to 
compare the behavior of cells encountering bound VEGF as opposed to soluble VEGF. To mimic 
the in vivo situation, a second approach consisted in generating a gradient of VEGF employing the 
technique of microfluidics. 
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6.3 Materials and Methods 
6.3.1 Materials 
The two polymers, poly(L-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG) and 
PLL-g-PEG/PEG-biotin were purchased from SurfaceSolutionS GmbH, Zürich. PLL-g-PEG are 
composed of a poly-L-lysine backbone of 20 kDa grafted with PEG side chains of 2 kDa. The 
grafting ratio g indicates the number of lysine monomer units per PEG side chain. In the 
PLL-g-PEG biotin, 20% of the side chains consist of PEG-biotin (3.4 kDa). PLL-g-PEGs were 
dissolved in HEPES buffer (10 mM 4-(2-hydroxy- ethyl) piperazine-1-ethane-sulfonic acid and 
150 mM NaCl, pH 7.4). 
 
6.3.2 Molecular-Assembly Patterning after Lift-Off 
The Molecular-Assembly Patterning after Lift-Off (MAPL) technique combines conventional 
photolithography and assembly of functional PEG-graft polycationic copolymers on a negatively 
charged oxide-coated wafer (Falconnet et al., 2004). A 6 nm thick Nb2O5 layer was sputtered onto 
the 12 mm diameter glass coverslips. Photolithography was performed in a cleanroom in which 
coverslips were spin coated with photoresist, UV-illuminated through a mask containing the desired 
patterns and developed. After washing and O2 plasma-treatment for 2 min, coverslips were coated 
with 100% PLL-g-PEG/PLL-g-PEG biotin (20% of PEG chains biotinylated) (1 mg/ml, for 40 min 
at RT). Here, adsorption from solution occurs via electrostatic interactions between the positively 
charged PLL backbone and the negatively charged metal oxide surface. Lift-off of the photoresist 
was performed using “Microposit Remover 1165”, an organic solvent. Coverslips were rinsed 
extensively with H2O and backfilling was performed with non-functionalized PLL-g-PEGs (1 
mg/ml, for 40 min at RT). For complex formation, Neutravidin (0.9 µM) was incubated with 
Heparin-biotin (1.2 µM) for 30 min at RT. The complex was exposed to the biotinylated pattern on 
the coverslips by incubating for 1h at RT. VEGF-A165 or VEGF-A121 (24 µg/ml in PBS with 1% 
BSA) were bound for 1h at RT. Coverslips were washed with PBS and used for immunostainings or 
for cell experiments. 
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6.3.3 Microfluidics 
Microfluidic channels of 50 µm depth were etched into a silicon wafer using a patterned 
photoresist mask and anisotropic KOH etching protocols. The wafer was cut into individual 
microfluidic chips. Each chip had a total of 20 microfluidic channels with channel width ranging 
from 30 µm to 100 µm. Channel width could be chosen according to needs. Coverslips were 
overlaid with a thin film of PDMS (Sylgard 184, Down Corning, USA mixed 10:1 (w/w) with 
curing agent) which was cured for 3h at 70°C. Prior to each use, the chips with the microfluidic 
channels were cleaned in a UV-Ozone cleaner (Jelight Co. Inc., USA) for 45 minutes. Chips were 
then placed on the PDMS-coated coverslip with the channels facing downwards. The channels were 
filled with 4 µl of protein in PBS at a concentration of 100 µg/ml. To prevent uncontrolled 
evaporation of the protein solution within the channels, an excess of protein solution was pipetted to 
both ends of the channels and the chips were incubated o/n in a humidity chamber at 4°C. The 
channels were rinsed with PBS by simultaneously pipetting PBS on one side and using a clean 
room paper on the other side as a flow promoter. The coverslips were separated from the chips and 
1% BSA was used to prevent unspecific binding on coverslips. After each use, the chips with the 
microfluidic channels were rinsed with PBS and ddH2O and dried under a N2-stream. Coverslips 
with the patterned proteins were then used for cell experiments. 
 
6.3.4 Cell culture 
Porcine Aortic Endothelial (PAE) cells expressing the Vascular Endothelial Growth Factor 
Receptor 2 (VEGFR-2) were grown on VEGF-A165 patterns for 4h at 37°C. Cells were fixed with 
3.7% formaldehyde in PBS for 10 min at RT followed by extensive washing with PBS. Cells were 
permeabilized with 1% NP40 in PBS for 10 min at RT. Primary antibodies (α-VR2 Sigma V9134 
1:300, α-VEGF Sigma 1:100 in PBS) were added o/n at 4°C. Then, coverslips were washed with 
PBS and incubated with fluorescently-labeled secondary antibodies (α-m-Alexa488 1:250, α-g-Cy3 
1:500) for 1h at RT. Samples were washed with PBS before they were embedded in gelvatol (15% 
gelvatol, 33% glycerol, 0.1% sodium azide). Images were acquired on an Olympus IX81 
epifluorescence microscope. 
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6.4 Results 
6.4.1 VEGF Immobilization through Molecular-Assembly Patterning by Lift-Off (MAPL) 
The process of photolithography on our glass coverslips was carried out in a cleanroom. The 
desired pattern was generated on standard glass coverslips. The MAPL technique developed at ETH 
Zürich (Falconnet et al., 2004) was successfully adapted to the immobilization of VEGF-A165 
(Fig 6-1). 
 
 
 
 
Figure 6-1: Molecular patterning after Lift-Off strategy for the immobilization of VEGF-A165. 
(A) Photoresist is patterned on niobium-coated coverslips by UV-illumination. (B) PLL-g-PEG-biotin are 
immobilized by spontaneous assembly. (C) Photoresist is lifted-off. (D) Non-functionalized PLL-g-PEGs are 
used for the backfill to prevent unspecific protein adsorption. (E) Heparin-biotin preincubated with 
Neutravidin is bound to the PLL-g-PEG-biotin pattern. F: VEGF-A165 binds to Heparin via its heparin-binding 
domain. Original artwork (inspired by (Sala et al., 2010)). 
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Using this technology, we created patterns of functionalized PLL-g-PEG-biotin in a 
nonfouling, protein-resistant PLL-g-PEG background. For backfilling, proteins such as BSA could 
also be used instead of PLL-g-PEGs to prevent unspecific binding (data not shown). 
PLL-g-PEG-based copolymers directly conjugated with biotin were used to immobilize 
Neutravidin. Correct patterning was checked by binding Alexa488-labeled Streptavidin instead of 
Neutravidin (Fig. 6-2). Patterns ranging from 100 µm thick lines down to 5 µm could be visualized.  
 
 
 
 
Figure 6-2: Immobilization of Streptavidin-Alexa488 on the PLL-g-PEG biotin pattern produced by 
MAPL. 
Patterned chips were incubated with 50 µg/ml Streptavidin-Alexa488 for 30 min at RT. The two figures show 
patterns with different dimensions. Depending on the mask used in the photolithographic process, various 
patterns could be generated. 
 
 
  
500 µm 
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Commercially available heparin-biotin was incubated at a predetermined ratio with 
Neutravidin and the complex was bound to the PLL-g-PEG biotin pattern on the coverslips. Next, 
we made use of the natural affinity of VEGF-A165 to heparin to indirectly couple the protein to 
patterned surfaces. VEGF-A121 which does not have a heparin binding site was used as a negative 
control. VEGF-A165 was immobilized via its heparin-binding domain and the specific 
immobilization of VEGF to the surfaces was studied by immunostaining (Fig. 6-3). For this, VEGF 
was visualized with an anti-VEGF antibody specific for both VEGF isoforms, VEGF-A165 
and -A121. The expected pattern could be seen with VEGF-A165 showing a strong fluorescence 
staining whereas VEGF-A121 gave a diffuse signal and therefore as expected had not bound 
specifically to the heparin. 
 
 
 
Figure 6-3: Immobilization of VEGF-A165 via heparin on the PLL-g-PEG biotin pattern. 
Patterned chips were incubated with Heparin-biotin (1.2 µM) preincubated with Neutravidin (0.9 µM). VEGF-
A165 (left and middle image) or VEGF-A121 (right image) was added at a concentration of 24 µg/ml at RT for 
1 h and detected with an anti-VEGF antibody. A Cy3-labeled secondary antibody was used.  
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6.4.2 Cell attachment to immobilized VEGF-A165 
After having successfully immobilized VEGF, the next step was to check whether VEGF-A165 
was still biologically active in this form and whether cells expressing VEGFR-2 were able to sense 
and bind the VEGF. Porcine aortic endothelial cells (PAE) expressing VEGFR-2 were grown on 
VEGF-A165 patterns for 2 h, fixed and immunostained with an anti-VEGFR-2 antibody. PAE cells 
migrated and divided on the generated micropatterns. Cells preferably attached to the areas where 
VEGF-A165 was immobilized (Fig. 6-4). Many cells that did not adhere directly to the VEGF-A165 
patterned lines but were found in between the pattern, did not show VEGFR-2 staining, further 
supporting our hypothesis that cells expressing the VEGFR-2 sense and bind to immobilized 
VEGF-A165. Using live-cell imaging, cells migrating from one patterned line to another could be 
followed (Fig. 6-5). In a next step it will be important to confirm that PAE-VEGFR-2 cells 
specifically bind to immobilized VEGF-A165 and that this effect is not due to different chemical or 
physical properties of patterned surfaces. Preliminary experiments have been performed where the 
surface was pre-incubated with an inhibitor against VEGF-A165 blocking its binding to VEGFR-2. 
On these surfaces, PAE-VEGFR-2 cells should no longer bind the immobilized VEGF. 
 
 
 
Figure 6-4: PAE-VEGFR-2 cells grown on VEGF-A165 patterned coverslips. 
Cells were grown on chips for 2h at 37°C, fixed, and (A) visualized with an anti-VEGFR-2 antibody (red) or 
(B) shown by phase-contrast. Arrows indicate filopodia of PAE-VEGFR-2 cell following patterned VEGF-A165. 
White square highlights a cell not expressing VEGFR-2 which does not adhere to the VEGF derivatized 
substrate potentially indicating unspecific adherence.  
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Figure 6-5: Migration of PAE-VEGFR-2 cells on VEGF-A165 patterns 
Migration of PAE-VEGFR-2 cells on VEGF-A165 patterns was monitored over 1.5 h. Figures show nine 
representative time points (A: 0 min, B: 12 min, C: 24 min, D: 36 min, E: 48 min, F: 60 min, G: 72 min, H: 84 
min, I: 96 min). The red star follows a cell spreading onto the pattern and the blue diamond a cell moving 
from one patterned line diagonally to another patterned line. 
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6.4.3 Generation of a protein gradient through microfluidics 
Reproducing a protein gradient on coverslips would be an elegant way to imitate the gradients 
of growth factors encountered by endothelial cells in vivo. Microfluidics, a technique allowing the 
manipulation of small volumes of protein solution through channels, seemed the appropriate 
technique to generate such a gradient. The experiments of VEGF-patterning by microfluidics were 
performed by my colleague Jörg Ziegler from the Laboratory of Micro- and Nanotechnology at PSI. 
Polydimethylsiloxane (PDMS) was used as a substrate on the coverslips. It belongs to a group of 
polymeric organosilicon compounds commonly referred to as silicones. PDMS is used in many 
applications due to its stability, low surface tension and lack of toxicity. The glass coverslips were 
covered with a thin film of PDMS which acts as an adhesive substrate and allowed better 
positioning of the channel-containing silicon dioxide chip on the coverslips. The resulting layer of 
PDMS is very thin and optically clear and therefore allows imaging of cells through the coated 
coverslip. Cells showed normal growth behavior on PDMS-coated coverslips. The silicon dioxide 
chip was placed on the coverslip and protein solution added to both ends of the microfluidic 
channels (Fig. 6-5). The channels immediately filled with the protein solution due to the capillary 
pressure. This pressure results from the hydrophilic property of the silicon dioxide and the 
micrometer sized dimensions of the channels. Channels were rinsed before removal of the silicon 
dioxide chip from the glass coverslip. The coverslip was then incubated with bovine serume 
albumin (BSA) to prevent unspecific protein binding. Binding of VEGF-A121 or -A165 was 
confirmed by immunofluorescence staining (Fig. 6-6 bottom). 
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Figure 6-6: Microfluidics strategy for the generation of a VEGF-A gradient on coverslips. 
Silicon dioxide chip containing the microfluidic channel was placed on a glass coverslip previously coated 
with a thin layer of PDMS. Protein solution (100 µg/ml VEGF-A121, -A165, or BSA) was placed at the entry of 
the channels and immediately filled the channels. Channels were rinsed and silicon dioxide chip removed. 
Coverslips were used for immunofluorescence stainings and cell experiments. Original artwork. 
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6.4.4 Cell growth on VEGF-A gradients 
PAE-VEGFR-2 cells were grown on the surfaces with immobilized VEGF-A121, -165, or BSA 
as a control. After 2 h of incubation at 37 °C, cells were fixed. Immobilized VEGF-A121 or -165 was 
detected with an anti-VEGF antibody and VEGFR-2 on the cells was visualized with an 
anti-VEGFR-2 antibody. As expected, cells exclusively attached to the immobilized VEGF-A121 
and -A165 and not to the albumin passivated surfaces. Furthermore, a weak gradient of VEGF-A165 
could be visualized. To enhance this gradient, lower concentrations of protein could be used. 
Preliminary experiments were carried out with such low amounts of VEGF-A121 and -A165 but will 
need further investigation. Experiments with inhibitors blocking VEGF-A binding to VEGFR-2 will 
need to be performed here as described above to confirm that cells bind specifically to the 
immobilized VEGF-A.  
 
 
 
 
Figure 6-7: PAE-VEGFR-2 cells grown on VEGF-A165 gradients. 
Microfluidic channels of 80 µm width were used. BSA (left), VEGF-A121 (middle), or VEGF-A165 (right) was 
immobilized on the PDMS surface by capillary flow through microfluidic channels. PBS containing 1% BSA 
was used to block unspecific protein binding. Cells were grown on chips at 37 °C for 2 h, fixed, and stained 
with an anti-VEGFR-2 antibody. Immobilized VEGF was stained with an anti-VEGF antibody. Arrows indicate 
VEGF-gradient. 
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6.5 Discussion 
In order to study VEGF signaling in a context reflecting the in vivo situation as closely as 
possible, we generated micropatterned surfaces of VEGF. Bound VEGF will allow us to gain 
insight into the differences in cell behavior arising from the various VEGF isoforms and elucidate 
in more details the process of angiogenesis. 
Many techniques of protein immobilization result in the immobilized protein being bound 
through different conformations on the surface and lead to a reduction of protein activity. We made 
use of the natural affinity of VEGF-A165 to HSPG to indirectly immobilize VEGF and in this way to 
obtain more uniform orientation of the molecules. This approach furthermore allowed us to 
circumvent the need of biotinylating VEGF, a process that generated an inactive protein (data not 
shown).  
We were able to immobilize VEGF on patterned surfaces using two different techniques 
which both have their advantages and disadvantages. In the MAPL approach, the indirect coupling 
of VEGF through immobilization of heparin ensures the correct positioning and orientation of 
VEGF. This technique is therefore useful to study the different cell responses to bound VEGF-A165 
versus soluble VEGF-A121. 
Microfluidic chips on the other hand present the major advantage of allowing the generation 
of protein gradients. This is achieved by varying the concentration of proteins and/or the flow 
velocity. The mechanisms by which endothelial cells respond to graded distributions of growth 
factors are still poorly understood and our gradient-generating system would be well suited to study 
these. We tried to combine gradient-formation and indirect VEGF-immobilization but encountered 
problems with the immobilization of heparin on the PDMS-coated coverslips. The problems might 
be due to the chemical properties of PDMS. After polymerization and cross-linking, PDMS displays 
an external hydrophobic surface. Plasma oxidation is used to make the surface hydrophilic through 
the presence of silanol groups (SiOH). Without further modification, the oxidized surfaces have a 
greater resistance to adsorption of hydrophobic and negatively charged species than unmodified 
PDMS. This my explain why negatively charged heparin does not bind. Direct binding of 
VEGF-A121 and –A165 to PDMS has proven successful.  
In both techniques, the growth factor retained its biological activity since cells expressing 
VEGFR-2 sensed and migrated towards the VEGF-A. We have preliminary indications that 
migration and attachment of cells is furthermore VEGF gradient-dependent since more cells 
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attached to areas where the concentration of micropatterned VEGF was higher as seen in double 
immunofluorescence staining (Fig. 6-6). 
The 2 h incubation time for cell attachment did not allow for an extensive study of VEGFR-2 
phosphorylation since this event takes place mostly in the first 15-30 min of receptor contact with 
the growth factor. In a next step, one could therefore consider growing cells on an extra surface 
before bringing them into contact with the VEGF-pattern (Anderson et al., 2009). PAE cells stably 
transfected with fluorescently tagged VEGFR-2 could be grown on patterns and used for 
performing live-cell imaging. This would allow to monitor VEGFR-2 internalization after 
stimulation and show differences between the signal output and the uptake of soluble VEGF-A121 
versus bound VEGF-A165. 
To study VEGF signaling in a cellular model reflecting the situation in vivo as closely as 
possible we will use vessel sprouting assays performed with endothelial cell spheroids. We will 
investigate the mechanisms responsible for vessel formation by VEGF isoforms. Endothelial cells 
cultured in standard two-dimensional cell culture lose many of their differentiated phenotypic 
properties. To overcome these limitations, endothelial cells are cultured as spheroids. 
In summary, we have developed microstructured biochips to better investigate the behavior of 
an endothelial cell encountering soluble or immobilized growth factors. These surfaces reproduce 
the in vivo situation where VEGF is bound to the ECM via HSPG and create a three-dimensional 
environment mimicking the natural environment of cells. Furthermore, the comparison of cells 
encountering soluble growth factor with cells being in contact with immobilized growth factor now 
becomes possible.  
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7 Conclusions and Outlook 
The concept that tumors are dependent on blood vessels surrounding them and the idea that 
inhibiting the formation of new blood vasculature in cancer might weaken the tumor, arose almost 
fourty years ago. Since then, a variety of angiogenic drugs have been developed and many of them 
have entered clinical trials. A promising target for anti-angiogenic therapies is VEGFR-2, the main 
mediator of angiogenic signaling in endothelial cells. VEGFR-2 was also the main object of 
investigation in my thesis. In a first project, we demonstrated the importance of VEGFR-2 ECD 
Immunoglobulin-homology domains 4 and 7 for receptor activation. With the help of these new 
insights into the molecular mechanisms underlying kinase activation, we were able to generate 
specific and high affinity binders to the ECD of VEGFR-2. We identified a DARPin that binds to 
D4 and inhibits VEGFR-2 in an allosteric fashion not interfering with ligand-binding. 
Potent and high-affinity inhibitors like the identified DARPin 6C8 could have potential in 
clinical applications such as in tumor vasculature imaging. Imaging in live mice could be carried 
out with different technologies such as positron emission tomography (PET) or single‐photon 
emission computed tomography (SPECT) using tagged variants of the DARPin. Furthermore, the 
potential of using the binders as angiogenesis inhibitors in vivo can be tested in chorioallantoic 
membrane (CAM) assays and later in mouse tumour models. 
In its current form, our D7-binding scFv does not inhibit ligand-induced VEGFR-2 activation. 
Future experiments could consist in reformatting the scFv into an IgG antibody and therefore 
increasing the probability of it inhibiting VEGFR-2 activation. Another possibility would be the 
bioconjugation of the scFv to drugs for site-specific delivery of these drugs. One could furthermore 
consider performing a phage display scFv screen against D4 of VEGFR-2 to identify D4 binders. 
Similarly to our identified D4 DARPin, D4 scFv might lead to allosteric VEGFR-2 inhibition. 
In a collaboration project with the Laboratory for Micro and Nanotechnology at PSI, we 
developed micropatterned biochips mimicking the in vivo environment of endothelial cells. Our 
microstructured biochips present useful tools to better investigate the behavior of an endothelial cell 
encountering a variety of soluble and matrix-bound growth factors. In a follow-up project, the 
in vitro findings will be supplemented by findings derived from in silico modeling of the 
angiogenesis process. The computational modeling will be performed by the group of Prof. Petros 
Koumoutsakos from the Department of Computer Science at ETH Zürich (Milde et al., 2008). 
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ALS   Amyotrophic lateral sclerosis  
AMD   Age-related macular degeneration 
ATP   Adenosine triphosphate  
BSA   Bovine serum albumin 
CDR   Complementarity determining region 
c-Kit   Stem cell factor receptor  
CRC   Colorectal cancer 
CSF1   Colony stimulating factor-1  
CSF1R   Colony stimulating factor-1 receptor  
DARPin    Designed Ankyrin Repeat Protein 
DMEM   Dulbecco's modified eagle's medium  
E.coli   Escherichia coli 
ECD   Extracellular domain  
ECM   Extracellular matrix  
EF   Enrichment factor 
EGF   Epidermal growth factor  
EGFR   Epidermal growth factor receptor  
EM   Electron microscopy  
eNOS   Endothelial nitric oxide synthase  
Eph   Ephrin receptor  
ELISA   Enzyme-linked immunosorbent assay 
ER   Endoplasmic reticulum  
ERK   Extracellular signal-regulated kinase  
FAK   Focal adhesion kinase  
FBS   Fetal bovine serum  
FDA   Food and Drug Administration  
FGF   Fibroblast growth factor  
FGFR   Fibroblast growth factor receptor  
Flk-1   Fetal liver kinase-1 = VEGFR-2 
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Flt-4   Fetal liver kinase-4 = VEGFR-3 
HEK293    Human embryonic kidney cells 293 
HEK293 Ampho   Human embryonic kidney cells 293 Amphotropic  
HIF-1    Hypoxia inducible factor-1  
HSPG    Heparan sulfate proteoglycan  
IMAC    Immobilized metal ion affinity chromatography  
KID    Kinase insert domain  
MALS   Multi-angle light scattering 
MAPK    Mitogen-activated protein kinase MAPK kinase  
MAPL   Molecular-Assembly Patterning after Lift-Off 
MEK    MAPK kinase  
MWCO    Molecular weight cut off  
NaPPi    Sodium pyrophosphate  
NCS   Newborne calf serum 
Ni-NTA    Nickel-nitrilotriacetic acid  
NO    Nitric oxide  
Nrp-1/-2    Neuropilin-1/-2  
NSCLC   Non-small cell lung cancer 
PAK2   p21-activated protein kinase-2 
PAE    Porcine aortic endothelial cells  
PAO    Phenyl arsine oxide  
PBS    Phosphate buffered saline  
PCR    Polymerase chain reaction 
PDMS   Polydimethylsiloxane  
PDGF    Platelet derived growth factor  
PDGFR    Platelet derived growth factor receptor  
PI3-K    Phosphoinositol-3 kinase  
PKC   Protein kinase C  
PLC-γ1    Phospholipase C gamma 1  
PlGF    Placenta growth factor  
PMSF    Phenylmethylsulfonyl fluoride  
pNPP    Para-nitrophenyl phosphate  
PTB    Phosphotyrosine binding domain  
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PVDF    Polyvinylidene fluoride 
rpm    Rounds per minute  
RTK    Receptor tyrosine kinase  
SAPK   Stress activated protein kinase 
SCF    Stem cell factor  
ScFv   Single-chain variable fragment 
SDS-PAGE    Sodium dodecylsulfate polyacryl gel electrophoresis  
SH2   Src homology-2 domain  
Shb   Src homology-2 protein in beta-cells  
SHP1/2   Src homology phosphatase-1/-2  
SNP   Single nucleotide polymorphism 
sVEGFR   Soluble VEGFR  
TK   Tyrosine kinase 
TMB   3,3’,5,5’-tetramethylbenzidine substrate solution  
TMD   Transmembrane domain 
TSAD   T cell-specific adaptor 
UDM   n-Undecyl-β-D-maltopyranoside  
VEGF   Vascular endothelial growth factor  
VEGFR   Vascular endothelial growth factor receptor  
VPF   Vascular permeability factor / VEGF 
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Vascular endothelial growth factors (VEGFs) constitute a family of six polypeptides, VEGF-A, -B, -C, -D, -E and
PlGF, that regulate blood and lymphatic vessel development. VEGFs specifically bind to three type V receptor
tyrosine kinases (RTKs), VEGFR-1, -2 and -3, and to coreceptors such as neuropilins and heparan sulfate
proteoglycans (HSPG). VEGFRs are activated upon ligand-induced dimerization mediated by the extracellular
domain (ECD). A study using receptor constructs carrying artificial dimerization-promoting transmembrane
domains (TMDs) showed that receptor dimerization is necessary, but not sufficient, for receptor activation
and demonstrates that distinct orientation of receptor monomers is required to instigate transmembrane
signaling. Angiogenic signaling by VEGF receptors also depends on cooperation with specific coreceptors
such as neuropilins and HSPG. A number of VEGF isoforms differ in binding to coreceptors, and ligand-
specific signal output is apparently the result of the specific coreceptor complex assembled by a particular
VEGF isoform. Here we discuss the structural features of VEGF family ligands and their receptors in relation
to their distinct signal output and angiogenic potential.
© 2009 Elsevier B.V. All rights reserved.
1. Biology of VEGF family growth factors and their receptors
1.1. Introduction to VEGF
Vascular endothelial growth factors, VEGFs, were originally
discovered as vascular permeability factor, VPF, an activity released
by tumor cells that promotes vascular leakage [1]. It is now clear that
VPF represented a biological activity attributable to a family of
polypeptide growth factors that are encoded by several genes
regulating blood and lymph vessel formation during embryonic
development, in wound healing, and in maintaining vessel homeo-
stasis in adult organisms. Excess or reduced production of VEGF
results in imbalanced formation of blood or lymphatic vessels and
causes many human diseases. VEGFs specifically interact with
hematopoietic and endothelial precursor cells such as angioblasts,
and with differentiating and mature endothelial cells.
Mammalian VEGF-A, -B, -C and placenta growth factor (PlGF) are
required for blood vessel formation while VEGF-C and -D regulate the
formation of lymphatic vessels [2,3]. In addition, orf family para-
poxviruses encode VEGF-A homologues called VEGF-E, which show a
high degree of structural identity with VEGF-A [4–6]. Despite only 25–
35% amino acid sequence identity with VEGF-A they bind with
comparable affinity to VEGFR-2 [7–9]. Moreover, VEGF-E family
members lack a heparin binding domain and vary in their abilities
to bind neuropilins [7,8]. Several VEGF-like proteins, now called
VEGF-F, have also been isolated from snake venoms and reported to
have biological activity similar to VEGF-A165 [10,11]. Vammin and VR-
1 from the venoms of Vipera ammodytes ammodytes (Western sand
viper) and Daboia russelli russelli (Russell's viper), which share ∼50%
amino acid sequence identity with VEGF-A165, strongly stimulate
proliferation of vascular endothelial cells in vitro and induce arterial
hypotension in rats. Another VEGF-F variant from Trimeresurus
flavoviridis snake venom, Tfsv-VEGF, efficiently promotes vascular
permeability similar to VEGF-A165, while stimulation of endothelial
cell proliferation by Tfsv-VEGF is negligible [12].
Proteolytic processing and alternative splicing give rise to a wide
variety of VEGF isoforms with distinct biological activities [13,14].
Fig. 1 shows a schematic representation of the most common splice
variants of VEGF-A. All isoforms contain exons 1–5 and either exon 8a
or 8b. A 26 amino acid signal sequence (exon 1 plus 4 amino acids of
exon 2) is cleaved off during secretion. The VEGFR-1 and -2 binding
domain consists of amino acids 1–109 and the VEGFR interaction sites
are located at opposite poles of the dimeric molecule [15,16].
Variable combinations of exons 6–8 encode additional basic
sequences that mediate binding to heparan sulfate (HS) and which
can be released from full length VEGFs by plasmin cleavage [17]. Exon
6a, present only in VEGF-A 206, 189, 162, 145 and partially in VEGF-
A183, is a highly basic stretch of 24 amino acids that confers binding to
HS and, as shown for VEGF-A145, to components of the extracellular
matrix of corneal endothelial cells distinct from HS [18]. Exon 6b has
so far only been identified in the less well characterized VEGF-A162
and in the longest isoform, VEGF-A206. VEGF-A 165, 183, 189 and 206
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contain an additional sequence encoded by exon 7 that also confers
HS binding due to its basic properties and thus limits ligand
diffusibility in tissues. The different HS binding affinities conferred
by exons 6 and 7 result in specific spatial distribution of the different
isoforms. VEGF-A189 and VEGF-A206 bind HS with high affinity
through their exon 6a and 7 encoded basic stretches. Consequently,
they remain tightly bound to the ECM, but can be released by cleavage
with plasmin, urokinase or matrix metalloproteases [14,19–21] or by
disruption of the HS matrix with heparinase [19]. VEGF-A145 [18] and
VEGF-A165 have intermediary affinity to the ECM, while VEGF-A121,
lacking exons 6 and 7, is freely diffusible [19].
All VEGF-As, except VEGF-A148, end with either exon 8a or 8b.
Alternative splicing of exon 8 results in the formation of two families
of proteins of identical length but differing in the carboxyterminal six
amino acids. Exon 8b encodes the amino acids SLTRKD-COOH in place
of the exon 8a sequence CDKPRR-COOH [22]. VEGF-A165b, the first
member of the VEGFxxxb family to be described, was found to be
present in normal tissue from kidney, but was not expressed by
malignant tumor cells [22]. Additional members of the VEGFxxxb
family identified so far include VEGF-A121b, VEGF145b, VEGF-A189b
and unspecified larger isoforms [23] as well as VEGF-A183b [24]. It is
now clear that proteins of the VEGFxxxb family make up a major
fraction of VEGF-A in most normal tissues [22,24–26], whereas their
expression is negligible in cancer cells [23,27,28]. At the molecular
level, the anti-angiogenic effects of the VEGFxxxb proteins can to a
large extent be ascribed to reduced signaling via VEGFR-2 [23]. These
isoforms are partial receptor agonists and, when coexpressed with
exon 8a proteins, may exert an inhibitory function by competition for
receptor binding. Interestingly, neither exon 8a nor 8b is required for
binding to VEGFR-1 or -2 [23,29] and both isoforms bind to VEGF
receptors with similar affinities and compete for binding to
endothelial cells and to immobilized VEGFR-2 in vitro [23]. VEGF-
A159, an artificially created truncated mutant of VEGF-A165 lacking
exon 8, retains VEGFR-1 and -2 binding. In contrast to VEGF-A165b,
this mutant does not inhibit angiogenesis in matrigel [29] suggesting
that competitive inhibition of VEGFR-2 binding does not fully account
for the anti-angiogenic effect mediated by VEGF-A165b. Taken
together, we propose that the exon 8b isoforms of VEGF-A are partial
receptor agonists capable to elicit some of the signal output of VEGFRs
such as for instance anti-apoptotic signaling or vessel permeabiliza-
tion (for details see also section 2.4.) [26,30].
The complex interplay of VEGF family proteins with VEGF
receptors and coreceptors is strictly required for shaping and
maintaining the functionality of blood vessels. Correct spatial
distribution of specific VEGF isoforms by differential ECM adherence
[31] and the coordinated signal output initiated by distinct VEGFs are
central for proper vessel organization.
1.2. Receptor specificity of VEGF
The biological functions of VEGF polypeptides result from binding
to several cellular receptors: type V receptor tyrosine kinases (RTKs)
such as VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4)
[32-34], neuropilin-1 and -2 (NRP-1, -2) [35] and heparan sulfate
proteoglycans (HSPG) [36]. Some VEGFs interact with multiple
receptors while others show very specific receptor binding proper-
ties. PlGF and VEGF-B are specific for VEGFR-1 [37,38], VEGF-Es bind
VEGFR-2 [4–6], and VEGF-C and -D bind VEGFR-2 and -3 [2,3].
Additional VEGF homologues were found in snake venoms collec-
tively designated VEGF-F, the seventh member of the VEGF family
[10]. VEGF-Fs bind to VEGFR-2 with dissociation constants similar to
VEGF-A165, but not to VEGFR-1, VEGFR-3 or NRP-1. More recently, a
novel VEGF-like protein from the Trimeresurus flavoviridis snake
venom (Tfsv-VEGF) with significantly different characteristics was
described. Tfsv-VEGF strongly binds to VEGFR-1, but only weakly
associates with VEGFR-2 [12].
In addition, VEGF-A splice variants show distinct binding patterns
to coreceptors such as HSPG and neuropilins. In all VEGF-A variants
exons 2–5 determine the specificity for VEGF RTKs 1–3 while exons 6
and/or 7 and 8 determine coreceptor binding. VEGFs can simulta-
neously bind two distinct receptors such as VEGFR-2 and neuropilin
even when these receptors are expressed separately on adjacent cells
[39]. This might be required for promoting endothelial cell migration
and cell guidance, for instance, when vessels form along tracks
defined by neural cells [40,41] or during endothelial tip cell guidance
[42,43].
Fig. 1. Schematic representation of selected VEGF-A variants as discussed in the text.
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1.3. VEGF receptor activation and signaling
Similar to other RTKs, signaling by VEGFRs is initiated upon binding
of a covalently linked ligand dimer to the extracellular receptor domain.
This interaction promotes receptor homo- and heterodimerization
followed by activation of the intracellular kinase domain. We have
recently shown how VEGF induces dimerization of the extracellular
receptor domain (ECD) [44]. VEGFR-2 monomers are dimerized upon
ligand binding to Ig-like domains 2 and 3 and dimers are further
stabilized by receptor–receptor contacts mediated by Ig-like domains 4
and7. Similar resultswerepublishedby Schlessinger's lab for the related
Kit and PDGF receptors [45,46]. We recently showed that distinct
dimerization-promoting transmembrane domains (TMDs) derived
from oncogenic variants of ErbB receptors activate VEGFR-2. Such
TMD constructs orient receptor monomers by intramembrane interac-
tions mediated by charged amino acids [173]. RTK activation thus
requires specific orientation of receptor monomers in an active dimer
which results from ligand-induced ECD rearrangement.
Activation of RTKs leads to phosphorylation of specific tyrosine
residues located in the intracellular juxtamembrane domain, the
kinase domain, the kinase insert domain and the carboxyterminal tail
of the receptor. The subsequent interaction between VEGFRs and
downstream signaling effectors is mediated through Src homology-2
(SH-2) and phosphotyrosine-binding (PTB) domains (reviewed in
[47]). Signaling by VEGF receptors has been reviewed comprehen-
sively in recent review articles [48,49]; here we therefore refer only to
some of the hallmarks of VEGFR-2 activation.
Y951, Y1054, Y1059, Y1175 and Y1214 were identified as the most
prominent phosphorylation sites of hVEGFR-2 [50]. Y1054 and Y1059
located in the activation loop were classified as autophosphorylation
sites important for the catalytic activity of the receptor kinase [51].
Site-directed mutagenesis led to the identification of Y801 and Y1175
as binding sites of phospholipase C-γ (PLC-γ) [52]. Phosphorylation
and activation of PLC-γ give rise to diacylglycerol and inositol
trisphosphate which stimulate protein kinase C (PKC) [53]. Mitogenic
signaling by VEGFR-2 is Ras independent andmediated by PKC via Erk
kinases [54–56].
VEGF-induced endothelial cell migration is mediated by the
adaptor protein VRAP, also known as T cell-specific adaptor (TSAD)
[57]. VRAP binding to Y951 leads to its phosphorylation and
recruitment of Src kinase which promotes actin reorganization and
cell migration [50]. Additionally, the adapter protein Shb binds to
phosphorylated Y1175 and leads to phosphoinositide-3-kinase
(PI 3-kinase)-mediated cytoskeleton reorganization as well as
activation of focal adhesion kinase (FAK) [58]. Cell migration and
capillary formation are regulated by VEGF through Gab1, which acts
as an adaptor for Grb2, PI 3-kinase and the tyrosine phosphatase
SHP2 [59,60]. VEGF-induced actin remodeling is also triggered
through the sequential activation of the small GTPase Cdc42 and
stress activated protein kinase (SAPK/p38) following phosphoryla-
tion of Y1214 [61]. This leads to phosphorylation and release of heat-
shock protein 27 (HSP27) 27. Early molecular events in cytoskeleton
reorganization include recruitment of the adaptor protein Nck and
the Src family kinase Fyn to VEGFR-2 and triggers phosphorylation
of p21-activated protein kinase-2 (PAK2) and activation of Cdc42
and p38 MAPK [62]. An additional important function of VEGF is
survival signaling via activation of PI 3-kinase and phosphorylation
of Akt [63]. Finally, signaling by VEGFR-2 is important for endothelial
cell specification, a process that might require activation of the Ras–
Erk pathway [64].
2. The role of coreceptors in VEGF signaling
Signaling by VEGFs depends on activation of three RTKs: VEGFR-1,
-2 and -3. In addition VEGF-A function is mediated by two types of
coreceptors: heparan sulfate proteoglycans and neuropilins.
2.1. Neuropilins
NRP-1 is a type I transmembrane glycoprotein originally identified
as the antigen of a specific monoclonal antibody raised against a
neuronal cell surface protein of Xenopus laevis involved in target
recognition of optic nerve fibres [69]. Later, it has been identified as a
receptor for class 3 semaphorins, playing a crucial role in growth cone
collapse during neural development [70–72]. A closely related
protein, NRP-2, has been identified a decade later as an additional
receptor for semaphorins [73,74]. Both proteins share a sequence
homology of 44% and show distinct, but overlapping patterns of tissue
distribution [74]. Independent of their function in neuronal guidance,
neuropilins play key roles in the development of the cardiovascular
system, cooperating with the function of the structurally unrelated
ligands of the VEGF family [75–77].
A plethora of interaction partners of neuropilins has been
identified, including VEGFR-1, VEGFR-2 [78], VEGFR-3 [79], FGF
receptor 1 [80], plexins [81], the cell adhesion molecule L1-CAM
[82], integrins [83], NIP/synectin/GIPC [84], galectin [85], fibroblast
growth factor (FGF) 1, 2, 4 and 7, hepatocyte growth factor/scatter
factor (HGF/SF), FGF-binding protein, prion protein and antithrombin
III [80]. Furthermore, heparin and heparan sulfate proteoglycans bind
to the extracellular domain of neuropilins and regulate their signaling
[86]. Neuropilins lack a sequence encoding an intracellular enzymatic
activity and are supposed to serve solely as coreceptors, thereby
modulating receptor output by VEGF RTKs. The observation that
VEGF-A165 is able to induce VEGFR-2/NRP-1 complex formation led to
the idea of VEGF-A165 bridging the two receptors [39,77,87,88]. In the
meantime it became clear that NRP-1 is also able to convey VEGF
autocrine signaling via the PI 3-kinase pathway in breast cancer cells
[89] and regulates endothelial cell attachment by acting on F-actin
organization independent of VEGFR-2 [90].
An elegant experiment by Wang et al. using a chimera of the
extracellular domain of EGF receptor fused to the transmembrane
and the intracellular domain of NRP-1 revealed that endothelial cell
migration, but not proliferation, is induced by the intracellular
domain of NRP-1 independently of VEGFR-2 [91]. The carboxy-
terminal three amino acids (SEA-COOH) are crucial for this process.
These amino acids are known to interact with the PDZ domain of
RGS-GAIP-interacting protein (GIPC, also termed neuropilin inter-
acting protein, NIP, or synectin) and are highly conserved among
neuropilins [84,92]. Ligand induced NRP-1/GIPC interaction is
required for angiogenesis, but not for vasculogenesis, in zebrafish
and for migration of endothelial cells [93]. GIPC interaction with
GAIP, which shares the same carboxyterminal three amino acids, is
implicated in the regulation of trafficking by clathrin coated vesicles
[92]. In the absence of experimental evidence, it is tempting to
speculate that this interaction is connected to the observed
internalization of NRP-1 after stimulation with VEGF-A165, but not
VEGF-A112 (originally presumed to represent VEGF-A121, see below)
which does not bind NRP-1 [94]. In fact, trafficking of NRP-1 and
VEGFR-2 seems to play a key role in VEGF-A165 induced signaling.
Clathrin dependent endocytosis of the VEGFR-2/NRP-1 complex
was observed upon VEGF-A165 stimulation [95]. This process
requires the presence of intracellular GIPC. Recently, it was
reported that VEGF and semaphorin-independent binding of NRP-
1 to GIPC controls internalization of α5β1 integrin to Rab5 positive
endosomes [96]. By interaction of GIPC with the motor protein
Myo6, cointernalization of α5β1 integrin and neuropilin at cell
adhesion sites leads to endothelial cell attachment to fibronectin.
Another line of evidence suggests that interaction with GIPC via the
carboxyterminal SEA motif is required for formation of a trimeric
VEGF-A/VEGFR-2/NRP-1 complex [97]. A careful analysis of all
processes associated with receptor internalization following ligand
stimulation is required to fully understand the role of neuropilins in
receptor trafficking.
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2.2. VEGF binding to neuropilins and its impact on VEGFR-2 signaling
The best characterized member of the VEGF-A family is VEGF-A165
(VEGF-A164 in mouse). Binding of VEGF-A165 to NRP-1 has been
discovered first by crosslinking of radiolabeled VEGF-A to the surfaces
of tumor cells and HUVECs [76]. NRP-1 was characterized as a low
affinity cell surface receptor that enhances chemotaxis upon stimu-
lationwith VEGF-A165 when coexpressedwith VEGFR-2 and enhanced
VEGF-A/VEGFR-2 complex formation on porcine aortic endothelial
(PAE) cells [76].
The molecular mechanism of VEGF-A signaling via NRP-1 has long
remained elusive, given the lack of intracellular enzymatic activity of
NRP-1 and the rather low affinity of VEGF-A165 for NRP-1 compared to
VEGFR-2 [76,78]. It is now becoming clear that trimeric coreceptor
formation of VEGF-A, VEGFR-2 and NRP-1 is essential, but not
sufficient, for induction of angiogenesis.
Experiments using antibodies selectively blocking VEGF-A165/
NRP-1 interaction show that VEGF-induced phosphorylation of
VEGFR-2 and the downstream signaling kinases of the Erk and Akt
families is not affected by VEGF-A/NRP-1 binding [125]. Similarly, it
was shown that formation of the trimeric coreceptor complex is not
required for activation of VEGFR-2, PLC-γ, Erk1 and Akt [121].
Signaling by VEGF-A variants defective for NRP-1 binding is, however,
more transient [29]. A comprehensive screening approach investigat-
ing VEGFR-2 activated kinases showed that stable coreceptor complex
formation is required for activation of p38 MAPK, for angiogenic
sprouting and for vascular plexus formation in embryoid bodies [121].
Thus, rather than affecting VEGFR-2 activity directly, NRP-1 is likely to
modulate signaling kinetics and the activation of specific signal output
via VEGFR-2. A possiblemechanism explaining NRP-1 functionmay be
that coreceptor complexes are processed differently than VEGFR-2
alone. So for instance receptor turnover and localization in endocytic
vesicles might be altered resulting in different signal output. Finally,
VEGF-A165 mediates VEGFR-2/NRP-1 complex formation also in trans
when the receptors are expressed on separate cells [39], or when the
NRP-1 extracellular domain is administered as a soluble protein
suggesting a role in juxtacrine signaling [88].
The NRP-1 binding epitope of VEGF-A was attributed to exons 7
and 8 [77], consistent with the observation that VEGF-A121 did not
bind to NRP-1 [76]. More recent results show that the short
carboxyterminal sequence encoded by exon 8a confers specificity
towards NRP-1. Tuftsin, an immunostimulatory peptide homologous
to the VEGF-A165 carboxyterminus, specifically binds to NRP-1 and
inhibits VEGF-A165 induced autophosphorylation of VEGFR-2 [112].
Alanine scanning mutations of the peptide ATWLPPR, a VEGF-A exon
8a homologue shown to inhibit VEGF-A165/NRP-1 binding and VEGF
mediated angiogenesis [113,114], confirms the importance of the
terminal arginine residue in NRP-1 binding. Interestingly, in the free
peptide, the prolines are in the trans conformation [115].
VEGF-A121 binding to VEGFR-2 is similar to that of the longer
isoforms. However, autophosphorylation of VEGFR-2 elicited by
VEGF-A121 is attenuated and this may be due to altered binding to
coreceptors [87]. There has been some confusion on binding to
neuropilins as a result of the fact that a commercially available source
of VEGF-A121 used by several laboratories was actually truncated and
represented VEGF-A112 [116,117]. This variant lacks part of exon 5 and
the entire exon 8 sequence that is now recognized to mediate NRP-1
binding [29,39,117]. VEGF-A121 is indeed able to bind NRP-1, though
more weakly than the longer VEGF-A isoforms, confirming that exon
8a confers specificity towards NRP-1.
The two most remarkable features of the exon 8a encoded
sequence are a highly basic stretch at the carboxyterminus, appar-
ently important for binding to HS [118] and NRP-1 [39] and a cysteine
residue in position 160. In VEGF-A165, C160 and the exon 7 encoded
C146 form a disulfide bridge [119], resulting in a restrained
conformation of the carboxyterminal tail [118]. By this arrangement,
the exon 7 and 8 encoded sequence is held in close proximity to the
VEGF receptor binding site. Mutation of C146 prevents this disulfide
bridge from forming and has been shown to reduce VEGF-A activity
such as induction of vascular permeability [120]. This disulfide bridge
apparently maintains the functionality of the HS binding epitope by
properly positioning the carboxyterminal basic residues. Recent work
in our laboratory showed that amutant VEGF-A165, in which C160was
mutated to serine, is indeed unable to bind heparin [39]. Remarkably,
this mutant was also unable to bind to NRP-1, showing that binding to
NRP-1 and HS is interdependent. The inability of exon 8b VEGF-As to
promote the formation of the trimeric VEGF-A/NRP-1/VEGFR-2
complex has been drawn on to explain its reduced angiogenic
potential. NRP-1 binding gain and loss of function mutants indeed
show a strong correlation between neuropilin binding, coreceptor
complex formation and angiogenesis in embryoid body assays
[39,121].
The failure of VEGF-A165b to induce vasculogenesis has recently
been related to the fact that phosphorylation of mVEGFR-2 at Y1052
and Y1057 (Y1054/Y1059 in hVEGFR-2), located in the activation loop
of the tyrosine kinase domain [122], is substantially lower after
stimulation with VEGF-A165b, compared to VEGF-A165, VEGF145 or
VEGF-A121 in cells expressing VEGFR-2 and NRP-1, whereas Y949 and
Y1212 (Y941/Y1214 in hVEGFR-2) phosphorylation levels were
comparable [123]. Earlier work by our group had already established
that phosphorylation of Y1175 in human and bovine VEGFR-2 upon
stimulation with VEGF-A165b is delayed andmore transient compared
to VEGF-A165, resulting in reduced signaling through the MAP kinases
Erk-1 and -2 [29]. Kawamura et al. suggested that VEGF-A165b fails to
rotate the VEGFR-2 monomers into a position that allows for efficient
phosphorylation of Y1052 and Y1057 in receptor dimers [123]. In fact,
it has been shown that VEGFR-2 activation depends on specific
rotational restraints of receptor monomers in ligand-induced dimers
(Dell'Era Dosch and Ballmer-Hofer, unpublished). Whether VEGF-A
exon 8a is indeed required to correctly position the tyrosine kinase
domain of VEGFR-2 in coreceptor complexes remains to be estab-
lished. Taken together, we propose that exon 8b isoforms activate
VEGFRs and coreceptor complexes in specific ways eliciting distinct
signal output required for vessel homeostasis, but not for angiogenesis.
Important insights into neuropilin binding and coreceptor com-
plex formation were also gained by analysis of parapoxvirus-encoded
VEGF-E homologues. Distinct VEGF-E variants isolated from numer-
ous virus strains differ in their ability to interact with NRP-1 and HS
[7,9]. VEGF-E NZ2, for instance, binds NRP-1, but not HS. Whereas
VEGF-A requires interaction with HS to form a stable VEGF-A/VEGFR-
2/NRP-1 complex, VEGF-E NZ2 does so in the absence of an HS
binding site due to the presence of a high affinity NRP-1 binding
epitope (RPPR) located near the carboxyterminus [39,121]. Interest-
ingly, coreceptor complex formation involving VEGFR-2 and NRP-1
and the corresponding biological response are restored by replacing
exon 8a in VEGF-A121 by the peptide RPPR derived from VEGF-E NZ2.
Based on these data we propose that the structural context of the
carboxyterminal exon 8a encoded motif is crucial for the formation of
trimeric VEGF-A/VEGFR-2/NRP-1 complexes. HS binding conferred
by exon 7 is required to stabilize the interaction of VEGF-Awith NRP-1
and presumably to alleviate electrostatic repulsion between the HS
binding domains of VEGF-A and its receptors. On the other hand,
despite the presence of exon 8a, VEGF-A145 was shown not to bind to
NRP-1, yet showed affinity for NRP-2 [124]. These findings suggest
that exons 7 and 8a are required for binding to NRP-1, while exon 6
and 8a sequences cooperate in NRP-2 binding.
2.3. Heparan sulfate proteoglycans
Heparan sulfate proteoglycans are ubiquitous components of the
cell surface and of the extracellular matrix (ECM), consisting of a
protein core, to which one or more glycosaminoglycan (GAG) chains
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are covalently attached. Heparan sulfate is an anionic GAG built from
repeating disaccharides composed of an uronic acid (either D-
glucuronic acid or its C5 epimer L-iduronic acid) and a derivative of
D-glucosamine that can be either N-sulfated or N-acetylated. Clusters
of N-sulfated disaccharides, referred to as S-domains, are flanked by
transition domains of alternating N-acetylated and N-sulfated units,
the T-domains. These sulfated regions are separated by stretches rich
in N-acetylation, the NA domains. Considerable heterogeneity is
further introduced by variable degrees of O-sulfation at C2 of the
uronic acid unit, as well as C3 and C6 of D-glucosamine in the NS and
alternating domains. Typically, HS chains reach lengths of 40–200
monosaccharide units. The fine structure and disaccharide distribu-
tion of HS chains is dependent on the tissue origin and therefore
contributes to tissue specific signaling [65]. Heparin is an unusual HS
in that it is composed primarily of extended NS domains with a 2-O-
sulfated iduronic acid and 6-O-sulfated, N-sulfated glucosamine
containing disaccharide as major constituent. It is usually not
presented on the cell surface but stored in cytoplasmic granules of
mast cells. Binding of protein ligands to the highly negative heparin
chains depends predominantly on electrostatic interactions mediated
by the sulfate substituents (for reviews on the function of heparin see
[66-68]).
2.4. The role of heparan sulfate proteoglycans in VEGF function
The interaction of VEGF-A165 with HS has been located to the
carboxyterminal heparin binding domain (HBD) and was shown to
depend on basic residues in exons 6 and 7. Site-directed mutagenesis
experiments identified arginine residues R123, R124 and R159 of
VEGF-A165 as crucial residues for the interaction with HS [98]. This
finding is supported by the refined NMR structure of the HBD [99],
where these residues are localized on a contiguous binding surface on
one face of the domain. Together with K125, K140, R145, R149 and
R156 they form an electropositive patch positioned to interact with
negatively charged HS (Fig. 4). Surprisingly, both VEGF-A165b and the
C160S VEGF-A165 mutant, which is unable to form the disulfide bridge
between C146 and C160, have lost their HS binding potential,
suggesting that the exon 8a encoded sequence is required to maintain
proper folding of the HBD. Instead of or in addition to the described
interactions, VEGF-A isoforms containing exon 6a (VEGF-A145, VEGF-
A162, VEGF-A183, VEGF-A189 and VEGF-A206) strongly bind HS through
this highly basic stretch. No structural information is available on this
interaction, but the abundance of positively charged residues (13 of
25 amino acids) suggests strong ionic interactions. Exon 6b, in
contrast, does not confer binding to HS due to the lack of basic
residues, and the combination of exons 6a and 6b present in VEGF-
A162 leads to only weak binding [100]. VEGF-A145 is an isoform
initially identified in tumor cells from the female reproductive system
that contains exon 6a and 8a, but not 7. As expected by the presence of
exon 6a, VEGF-A145 strongly binds to the extracellular matrix.
Surprisingly, this protein cannot be released from the ECM by
heparinase [18].
Robinson et al. performed an extensive analysis on the domain
structure within HS chains required to bind to VEGF-A165 [101]. They
found no correlation between binding and the presence of specific
disaccharides or the overall level of sulfation. Rather, the minimal
requirement for VEGF-A165 binding is a fragment containing at least
one S-domain and the flanking T-domains. In contrast to members of
the FGF family, VEGF-A failed to bind to isolated S-domains. Both N-
sulfation and 6-O-sulfation in the HS S-domains are crucial for VEGF-
A165 binding, whereas 2-O-sulfate groups and carboxylate groups
contribute to a lesser extent [101], a finding in agreement with
previous results obtained with heparin [102]. VEGF-A binding to HS
therefore differs from HGF and FGF-2 which strictly require 2-O-
sulfation. Different patterns of HS chains could thus contribute to the
tissue specificity of growth factor signaling.
Docking studies predict numerous contacts between the electro-
positive patch of the VEGF-A165 HBD on the one hand and
carboxylate and sulfate groups of six HS monosaccharides on the
other hand, with a high degree of flexibility regarding the orientation
and positioning of the GAG in the binding groove. Indeed, under
nonphysiologically low salt conditions, oligomers as short as
8 monosaccharide units bind to VEGF-A, whereas longer oligomers
of 22–26 are preferentially bound from mixtures of K5 lyase treated
HS. This suggests the engagement of both HBDs of a VEGF-A165 dimer
in the complex [101].
Theoretically, binding of growth factors to HSPG can serve four
basic functions: (i) concentration of the growth factor at the cell
surface and presentation to cell surface receptors, (ii) engagement of
the HSPG in a coreceptor complex with altered binding or signaling
properties compared to a minimal growth factor/receptor complex,
(iii) restriction of growth factor diffusion to provide spatially
restricted signaling cues and (iv) creation of a growth factor
reservoir that can be released by hydrolytic processing of either
the HS chain or the growth factor [103]. A conclusive interpretation
of HS function in the context of the VEGF-A/VEGFR-2/NRP-1
complex proves difficult since each of the components is on its
own capable to engage in HS binding and because NRP-1 itself is also
subject to GAG modification.
Gitay-Goren et al. [104] showed that VEGF-A165 binding to adult
bovine aortic endothelial cells (ABAE) and human vascular endothe-
lial cells (HUVEC) is increased by low concentrations (0.1–10 μg/ml)
of heparin. The effect of heparin was attributed to the presence of
VEGFR-2, since binding was not increased in cells expressing only
VEGFR-1 [105]. A contribution of VEGFR-2 is further suggested by the
enhancement of VEGF-A165 binding to a soluble VEGFR-2-Fc fusion
protein by the addition of heparin in vitro [106]. Heparin fragments of
22–24 monosaccharides constitute the minimal size for binding
enhancement, while shorter heparin fragments are inhibitors [107].
An important role of cell surface HSPG was suggested by the
observation that VEGF-A165/VEGFR-2 binding is reduced in cell lines
defective for HS synthesis [108] or following treatment of cells with
heparinase [104], yet is restored by the addition of exogenous
heparin. Interestingly, while the VEGF-A121/VEGFR-2 interaction is
not altered by heparin in vitro [109], a VEGF-A165 variant that has
been rendered incapable of binding to heparin by site-directed
mutagenesis is unaffected in VEGFR-2 binding and is biologically
active as judged by its ability to activate VEGFR-2 downstream
signaling via tissue factor promoting microvessel outgrowth from
aortic rings [98].
Chiang and Flanagan showed that the soluble extracellular domain
of VEGFR-2 isolated from conditioned medium is retained by heparin
sepharose, suggesting direct binding to HSPG [110]. Although the
involvement of other factors present in the medium could not be
excluded, this interaction was attributed to a short basic stretch
between Ig-like domains 6 and 7 [108]. A highly basic decapeptide
derived from that stretch binds heparin and inhibits VEGF-A165
binding to VEGFR-2 in the presence of heparin, suggesting a specific
interaction, rather than competition for VEGF. Only recently, a dose-
dependent direct interaction of VEGFR-2 with heparin was reported
[111].
2.5. Interaction of heparan sulfate with neuropilins
NRP-1 binds HS fragments of at least eight monosaccharides via its
combined b1b2 domains. Consistent with the observation that either
b1 or b2 alone fail to bind heparin [86], R359 and K373 in the b1
domain and R513, K514 and K516 in the b2 domain were determined
to be key mediators of HS dependent dimerization [126]. These
residues form a contiguous electropositive stretch on the NRP-1
surface that could conceivably accommodate 12 monosaccharide
units. HS binding to this groove located close to the observed tuftsin
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binding site might serve to properly align the b1 and b2 domains.
Interestingly, a HS tetradecasaccharide, but not shorter oligosacchar-
ides, triggers NRP-1 and NRP-2 b1b2 domains to form dimers.
Although neuropilin homo- and heterodimerization via their MAM
domains and TMDs have been implicated in semaphorin signaling by
several groups, the role of dimerization in VEGF signaling is less well
defined [71,127–130]. Yamada et al. showed that soluble dimeric
NRP-1 rescues VEGF-A165 mediated VEGFR-2 signaling in endothelial
cells from NRP-1 knockout mice in vitro [131]. Dimeric NRP-1 ECD
compensates vascular defects in mesoderm explants and embryos,
whereas monomeric NRP-1 inhibits angiogenesis. It was proposed
that VEGF is presented to VEGFR-2 by dimeric NRP-1, while
monomeric coreceptor acts as a decoy, competing for VEGF.
Besides influencing the VEGF-A/VEGFR-2 interaction directly, HS
modulates also VEGF-A/NRP-1 interaction and thereby the formation
of coreceptor complexes. Fuh et al. reported that the affinity of VEGF-
A165 to NRP-1 is greatly enhanced by the presence of heparin [78].
While an octasaccharide suffices to bind NRP-1, 20–24 monosaccha-
ride units are minimally required to enhance its interaction with
VEGF-A165 consistent with the idea that the protein ligands occupy
different binding sites on a single heparin oligosaccharide chain [86].
The optimal concentration was found to be 100 nM to 1 μM heparin
[78]. In vitro, the ability of NRP-1 to increase the affinity of VEGF-A165
to soluble VEGFR-2 is strictly dependent on the addition of HS [78]
suggesting that HS is required to stabilize a trimeric receptor/ligand
complex. We showed that a stable coreceptor complex can only be
induced by VEGF-A variants capable to bind both HS and NRP-1 and
concluded that HS is required to stabilize the VEGF-A/NRP-1
interaction [30].
NRP-1 itself is also modified by GAG in a cell type-specific manner
at the highly conserved S612 residue. A substantial fraction of NRP-1
from coronary artery smooth muscle cells is modified by chondroi-
tinsulfate (CS), whereas in HUVEC a smaller fraction is modified by HS
or CS. VEGF-A binding to the NRP-1 core protein is markedly increased
by the GAG modifications. Furthermore, VEGFR-2 degradation after
ligand stimulation is accelerated in endothelial cells expressing NRP-1
lacking GAG modification, resulting in more transient signaling. In
contrast, CS modified NRP-1 in smooth muscle cells reduces VEGFR-2
expression levels posttranslationally [132]. As VEGF-A forms com-
plexes with NRP-1 and VEGFR-2 expressed on separate cells [39], and
GAG modifications have been shown to potentiate VEGFR-2 signaling
in trans [133], the observed reduction of VEGFR-2 internalization
might be explained by VEGFR-2 being trapped in a stable trimeric
complex with NRP-1 expressed on adjacent cells.
2.6. Heparan sulfate proteoglycans are essential for cell proliferation and
embryonic development
The importance of correctly modified HS for cellular responses to
VEGF-A165 has been demonstrated by several groups. HUVEC cells
treated with sodium chlorate, an inhibitor of HS sulfation, fail to
proliferate in response to VEGF-A165 unless heparin or sulfate is added
to the medium. Importantly, desulfated heparins, including 2-O-
desulfated heparin, were not able to restore HUVEC proliferation. In
zebrafish, depletion of 6-O-sulfation by specific inactivation of the
sulfotransferase HS6TS-2 results in abnormalities in branching
morphogenesis of the caudal vein during embryonic development
[102]. Analysis of the endothelial markers revealed that primary
formation of axial vessels and sprouting of intersegmental vessels are
not dependent on the native sulfation pattern, but vascular remodel-
ing is impaired. Simultaneous reduction of HS6ST-2 and VEGF-A
expression had a synergistic effect and increased the frequency of
abnormalities, but an effect on additional HS binding growth factors
cannot be excluded [134].
Mammalian embryoid bodies derived from Ndst1/2−/− stem cells
defective in a sulfotransferase, which is essential for HS biosynthesis,
fail to respond to VEGF-A165 [133]. The addition of exogenous HS
could not substitute for the lack of correctly modified HSPG in this
system. Notably, coculture with cells expressing wild-type HSPG, but
not VEGFR-2, resulted in rescue of VEGF-A165 induced vascular
development. The response was accompanied by potentiated and
less transient activation of VEGFR-2 and could not be elicited by
binding of VEGF-A121. The authors propose that trapping of the
activated receptor complex by HSPG in trans prevents internalization
and degradation and thus accounts for prolonged signaling. This could
indicate a role for HSPG in juxtacrine signaling.
Heparin binding has also been shown to be important in
determining the spatial distribution of VEGF-A isoforms. Several
laboratories examined vascular development in mouse embryos
expressing specific splice isoforms of VEGF-A [31,135–137]. Taken
together, these data show that VEGF-A164/164 mice were healthy
while all the other mutants showed serious vascular defects. So for
instance endothelial cells at the tip of branching vessels develop
polarized filopodial extensions directed towards extracellular VEGF
deposits that guide the growing vessel [42]. In wild-type mouse
embryos secreted VEGF accumulates in patches close to its expression
sites and forms a steep concentration gradient. In mice expressing
exclusively VEGF-A120, however, the spatial distribution is much less
restricted due to the lack of attachment to the ECM via HS. Failure of
VEGF-A120 to attach to the ECM has severe repercussions on vessel
branching. Endothelial cells are preferentially integrated into the
lumen of existing vessels instead of forming new branch points,
resulting in thicker, less complex vasculature. In contrast, the
vasculature of mice expressing exclusively VEGF-A188 is excessively
branched with reduced vessel diameter. These defects are a
consequence of impaired polarization of the filopodial extensions of
endothelial cells in response to immobilized VEGF rather than
impaired cell proliferation [31]. Likewise, tumors expressing VEGF-
A188 develop a dense network of vessels, but are unable of recruiting
supplying vessels from their neighborhood, because tightly stroma-
bound VEGF-A188 cannot diffuse into the surrounding tissue [138]. In
contrast, VEGF-A120 is readily diffusible from the expressing tumor
and consequently large vessels are recruited from surrounding
tissues, which fail to develop a branched microvasculature.
Two HSPGs, perlecan and glypican, have been implicated in VEGF
signaling.
The extracellular matrix protein perlecan modulates processes as
diverse as cell adhesion, proliferation and apoptosis (reviewed in
[139]). Perlecan was shown to bind to VEGF-A via its HS side chains
and combined administration to HUVEC cells increases VEGFR-2
activation [140]. Perlecan knock-down in tumor cells results in
reduced proliferative response to VEGF-A165 and FGF [141]. Similarly,
perlecan knockdown in zebrafish leads to abnormal VEGF deposition
defects in intersegmental vessel formation. The phenotype can be
partially rescued by injection of VEGF-A165 suggesting a dual role for
perlecan as a regulator of VEGF localization and mediator of signaling
via VEGFR-2 [140]. Glypican, a glycosylphosphatidylinositol anchored
cell surface protein expressed in the vascular system, was also shown
to bind to VEGF-A165, but not to VEGF-A121. Glypican potentiates
VEGF-A165 binding to soluble VEGFR-2 and to HUVEC cells and
restores VEGFR-2 binding of VEGF-A165 following damage by
oxidizing agents [142]. However, this effect does not need to be
specific for glypican, since heparin or HS could recover damaged
VEGF-A165 activity as well.
3. Structure of VEGF and its receptors
The structure of VEGF family proteins and their receptors is the
subject of intense research and several high resolution structures for
VEGF proteins are available. Here we review these structural data and
discuss the functional implications derived from this extensive data
set.
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3.1. The structure of VEGF-A
The crystal structure of the VEGF receptor binding domain of
VEGF-A was first reported by Muller and co-workers [15]. The VEGF-A
structure consists of a homodimer that is covalently linked by two
intermolecular disulfide bonds between C51 and C60 (Fig. 2A). It
contains a cysteine knot motif, which has also been described for
other VEGF family members and related growth factors, such as PDGF
and TGF-β 2 [143–149]. The knot consists of an eight residue ring
formed by the backbone atoms of residues 57–61 and 102–104 and
two intramolecular disulfide bridges, C57-C102 and C61-C104, with a
third disulfide bridge (C26-C68) that passes almost perpendicularly
through the center of the ring. A central four-stranded antiparallel β-
sheet formed by two pairs of twisted antiparallel β-strands, referred
to as β1, β3, β5 and β6, extends from the cysteine knot motif. A single
hydrogen bond connects β3 and β5, which makes the β-sheet highly
irregular. Loop 1 connecting β1 and β3 contains a single turn of an α-
helix as well as a short β-strand. This strand, together with the end of
β5 and the beginning of β6, forms a short three-stranded β-sheet at
the opposite end of the molecule from the cysteine knot. Residues
from this sheet, helix α2, and the loops L1 and L3 (β5–β6), together
with residues from the aminoterminal α-helix of the opposite
monomer, form a small hydrophobic core, which has been proposed
to provide additional stabilization to the four-stranded central sheet
[146]. The two monomers adopt an antiparallel orientation related by
a 2-fold axis perpendicular to the plane of the β-sheets.
Based on a comprehensive mutagenesis study eight VEGFR-2
binding determinants have been identified that cluster into two
symmetrical binding surfaces at either pole of the VEGF-A homodimer
[15].Within each of these surfaces the side chains of the eight residues
cluster into two solvent accessible ‘hot spots,’ which are exposed on
the same pole of the molecule. The larger hot spot comprises residues
I43, I46, I83, K84, P85 and E64 (Fig. 3, red). The smaller hot spot
contains residues F17 and Q79 (Fig. 3, orange). The hypothesis of
VEGF-induced dimerization of VEGFRs by binding a receptor molecule
at either pole of VEGF-A has later been corroborated by the crystal
structure of a complex between the receptor-binding domain of
VEGF-A and VEGFR-1 domain 2 (Fig. 2B) [16] and by mutational and
biophysical studies by Fuh and coworkers [150]. These studies
showed that two molecules of VEGFR-2 are dimerized across the
VEGF subunit interface and induce signaling. The crystal structure of
the complex revealed predominantly hydrophobic interactions of
VEGFR-1 domain 2 with the poles of the VEGF-A dimer [16]. No major
conformational changes were observed in the overall structure of the
receptor domain-bound VEGF-A compared to the structure of the free
form. The largest differences were observed in the loop regions L1 and
L3, which also show a high degree of flexibility in the free VEGF-A
structure [15]. Moreover, deletion experiments showed that Ig-like
domains 2–3 are sufficient for tight binding to VEGF-A. However, in
the absence of X-ray crystallographic data for such a receptor–ligand
complex, the orientation of receptor monomers in ligand complexes
remains unknown. High resolution structural information is urgently
needed to understand receptor activation and specificity of VEGF
family ligands in molecular terms.
In the VEGFR-1 domain 2 complex structure the carboxyterminus
of VEGFR-1 domain 2 points towards a 6.5 Å wide groove that extends
from the pole to the membrane-facing side of the two VEGF-
monomers (Fig. 3). Three side chains of the six large hot spot residues
are located in the walls of this groove, while the remaining hot spot
residues are at the membrane-facing side. According to these
structural features and the experimental evidence that a receptor
fragment of domains 2–3 binds 20-fold tighter to VEGF compared to
Fig. 2. Structures of VEGF-A and VEGFR-1 domain 2. Ribbon representations of (A) the nonliganded VEGF-A109 (‘bottom’ view looking up from the cell membrane; PDB code 1VPF)
and (B) the complex between VEGF-A109 and VEGFR-1 domain 2 (top panel: bottom view; bottom panel: side view; PDB code 1FLT). The two VEGFmonomers are shown in blue and
light orange, respectively; the VEGFR-1 domain 2 in red. Disulfide bonds are shown as yellow sticks. The secondary structure elements are labeled according to the original
references. The figure was prepared using PyMOL [170].
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domain 2 alone, it was proposed that in the native complex the linker
between the domains 2 and 3 may occupy the groove, positioning the
third domain in contact with the bottom face of VEGF [16]. Based on
these assumptions and on the available crystal structure of the
complex, a dimeric model of the receptor-binding domain of VEGF in
complex with domains 1–4 of VEGFR-1 was constructed, in which the
domain 2–3 linker occupies the groove, and domain 3 is in contact
with the bottom face of VEGF. In the proposed orientation the
carboxytermini of the domains 3 are in close proximity to allow direct
contacts between the domains 4 [16]. To date, no crystal structure of a
multidomain VEGF receptor complex is available to confirm this
model.
Fig. 3. Hotspots for VEGFR-2 binding. Surface representation of VEGF-A109 in complex with domain 2 of VEGFR-1 (lime ribbon representation; PDB code 1FLT). Both critical hotspots
for VEGFR-2 binding that were identified by mutational analysis are mapped onto the surface in red (‘large’) and orange (‘small’), respectively. The carboxyterminus of domain 2
(yellow sphere) points towards the groove. Positioning of the D2–D3 linker in the groove would place the domain 3 in a favorable orientation for the interaction with the remaining
hotspot residues.
Fig. 4. Solution structure of the HBD of VEGF-A. (A) Cartoon representation of the HBD in four different orientations (PDB code 1VGH, model 1; 90° rotations about the vertical axis in
the plane). The secondary structure elements are colored in orange and blue. The disulfide bonds are represented as yellow sticks. The amino- and carboxytermini are labeled. (B)
Electrostatic surface potential (calculated with the program DelPhi [171,172] mapped onto the surface of the HBD (same model and orientations as in (A)). The negative (red) and
the positive (blue) electrostatic surface potentials are contoured at ± 8 kT.
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3.2. The VEGF-A heparin binding domain
The carboxyterminal domain of VEGF-A165 comprises 55 residues
with no significant sequence homology to known proteins and
represents a unique heparin-binding domain [119]. It is highly basic
and contains eight cysteine residues that form four disulfide bonds.
The solution structure of the heparin-binding domain of VEGF-A165
was determined by homo- and heteronuclear NMR spectroscopy
[99,118]. The structure consists of two subdomains: the aminoterm-
inal subdomain (residues 110–139) contains a disordered region and
a single two-stranded β-sheet. The carboxyterminal subdomain
(residues 139–165) is well ordered and contains a short α-helix
packed against a two-stranded antiparallel β-sheet (Fig. 4). A cluster
of charged residues (R123, R124, K125, K140, R145, R149 and R156)
on one side of the carboxyterminal domain and an adjacent
disordered loop from the aminoterminal domain has been proposed
as putative HS binding site based on electrostatic surface potential
calculations [118]. However, no structural study of a complex
between the VEGF heparin-binding domain with a heparin fragment
has been reported to date to reveal the details of this interaction.
3.3. The structure of VEGF-B
Two VEGF-B isoforms, VEGF-B167 and VEGF-B186, are generated by
alternative splicing [151]. They exclusively interact with VEGFR-1, and
not with VEGFR-2 or -3 [38]. Moreover, both isoforms bind NRP-1.
Binding of VEGF-B167 to NRP-1 is mediated by the heparin-binding
domain, whereas binding of VEGF-B186 is regulated by exposure of a
short carboxyterminal proline-rich peptide upon proteolytic proces-
sing [152].
The crystal structures of VEGF-B [144] and of a complex with a
neutralizing antibody Fab fragment were recently reported [153]. The
overall structure of VEGF-B is similar to the known structures of other
cysteine knot proteins. Human VEGF-B (residues 10–108) shares 46%
sequence identity with human VEGF-A (residues 11–109) and 37%
sequence identity with human PlGF (residues 19–118) and super-
imposes onto the dimers of VEGF-A and PlGF with r.m.s. deviations of
1.3 Å and 1.6 Å, respectively [144]. Major conformational differences
have been observed in loops L1 and L3, which are important regions
for receptor binding. Based on a predictedmodel for the association of
VEGF-B with the second domain of VEGFR-1 and the structural data of
the native protein, N46, P62, V48, D63 and I83 of VEGF-B were
proposed to form hydrogen-bonding and van der Waals interactions
to H223 of VEGFR-1, contributing to VEGF-B/VEGFR-1 complex
formation. Six out of the eight hot spot residues of VEGF-A that
have been implicated in VEGFR-2 binding are conserved in VEGF-B
[15]. Moreover, different positioning of P86 in loop L3 has been
proposed to induce conformational differences in loop L3 that likely
prevent VEGF-B from binding to VEGFR-2. The interaction of a
neutralizing antibody with VEGF-B involves essential residues at each
pole of the VEGF-B homodimer. The interface is rather flat and largely
hydrophobic and lacks typical ‘knob-into-hole’ interactions as
observed in the receptor complexes of VEGF-A [16] and PlGF [154].
Substantial overlap was observed between the buried surfaces in the
VEGF-B/Fab complex and in the predictedmodel of VEGF-B/VEGFR-1,
which share 11 conserved residues. Accordingly, the neutralizing
effect of the antibodywas proposed to occur by steric hindrance of the
receptor binding interface and not as a consequence of induced
conformational changes in the ligand [153].
3.4. The structures of VEGF-C and -D
VEGF-C and VEGF-D share a similar architecture with other
VEGFs, including the cysteine knot motif. They are synthesized as
precursor proteins with long amino- and carboxyterminal propep-
tides flanking the VEGFR-binding domain. Upon secretion, proteo-
lytic cleavage of the propeptides releases the mature VEGF
homology domain with increased affinity to both VEGFR-2 and
VEGFR-3 [155,156]. Mature VEGF-C and VEGF-D have been described
as a mixture of covalent and noncovalent dimers [155–158]. To date,
no crystal structure has been reported for any of these two growth
factors. Besides the conserved cysteine pattern typical for cysteine
knot proteins, an additional cysteine residue is most likely located at
the dimer interface of both VEGF-C and VEGF-D and might interfere
with dimer formation by engagement to an intramolecular disulfide
bridge. Recently, a model of VEGF-D was designed and the cysteines
located at the subunit interface were mutated to study the effect of
these residues on the structural and functional properties of VEGF-D
[159]. The two conserved cysteines C44 and C53 were found to be
essential for VEGF-D activity. In contrast, the replacement of the
additional cysteine C25 by isoleucine, leucine or valine yielded novel
VEGF-D variants with increased biological activity [159]. In the
proposed model, cysteine C25 is located close to the conserved
cysteines C44 and C53. Accordingly, a regulatory function was
Fig. 5. Domain organization and structure of neuropilins. (A) Schematic drawing of the overall domain architecture of neuropilins. Neuropilins possess a ligand binding ectodomain
consisting of CUB (a1/a2) and F5/8 (b1/b2) domains, followed by a membrane proximal MAM (C) domain. A short membrane-spanning domain (TM) and cytoplasmic tail with a
PDZ binding motif comprise the remainder of the protein. CUB domains, orange/red; F5/8 domains, olive/dark green; MAM, light blue; TM, yellow. (B) Ribbon diagram of the NRP-1
b1 domain (PDB code 1KEX). The core of the β-barrel is formed by a three-stranded (orange) and a five-stranded (blue) antiparallel β-sheet. The six loops (L1–L6) extend at the top
of the β-barrel. (C) Ribbon diagram of the NRP-2 a1a2b1b2 structure (PDB code 1QQL). The domains are colored using the same color code as in (A).
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assigned to cysteine C25 that limits and modulates the activity of the
mature protein in vivo. Modulation of the exchange rate between intra-
and intermolecular disulfide bond formation, in response to changes in
the extracellular redox environment thereby enhancing the dimeric
stability of VEGF-D, was proposed as a potential regulatory mechanism
inherent to VEGF familymembers that have such an additional cysteine
residue at the dimer interface [159]. Structural data on VEGF-C or VEGF-
D will be required to prove this hypothesis.
3.5. The structure of VEGF-E
The crystal structure of the core region of VEGF-E NZ2 is very
similar to the structural homologs VEGF-A, VEGF-B, PlGF, and the two
snake venoms Vammin and VR-1 which superimpose with an r.m.s.
deviation of ∼1.0 Å [160]. Significant conformational differences are
observed only in loops L1 and L3. The exchange of individual
segments in loops L1 and L3 by the corresponding sequences from
PlGF abolished binding to VEGFR-2, whereas a simultaneous exchange
of both loops reduced binding and conferred the ability to VEGF-E to
interact with VEGFR-1. Moreover, the exchange of R46 to I in loop L1
significantly increased the affinity of VEGF-E for both VEGF receptors.
According to these observations, Pieren and coworkers suggested that
loop L2 with D63, E64 and E67 is essential for binding to VEGF
receptors, whereas the distinct orientation of loops L1 and L3
determines VEGF receptor specificity.
3.6. The structure of VEGF-F
The recently reported crystal structures of Vammin and VR-1
revealed high homology to VEGF-A (r.m.s.d. 1.2 Å for vammin and
1.6 Å for VR-1), but three distinct structural features differ from other
known VEGF structures [149]. First, the insertion of T86 causes a
different conformation in loop L3. Secondly, substantial differences in
electrostatic surface potential are observed. Vammin and VR-1 feature
a positive electrostatic surface potential in contrast to VEGF-A and
PlGF, which are negative. Thirdly, R82 and R86 form a tight framework
of salt bridges with E42, D45 and E93 that stabilizes the relative
orientation of the loops L1 and L3.
3.7. VEGF receptor and neuropilin structures
Structural information on VEGF receptor ectodomains is limited to
the solution structure of VEGFR-1 domain 2 in its nonliganded form
[161], and to the crystal structures of VEGFR-1 domain 2 in complex
with VEGF-A [16,161] and PlGF [154]. The crystal structures revealed
that this domain is a member of the I-set of the immunoglobulin
superfamily [162]. VEGFR-1 domain 2 consists of a sandwich formed
by two β-sheets, one consisting of five strands, the other of three. The
strands in the three-stranded sheet are rather short and consist of
only three or four residues. The hydrophobic core buries a disulfide
bridge between C158 and C207 that connects the two β-sheets [16].
An unusual feature is a region near the aminoterminus that bulges
away from the domain rather than pairing with the neighboring β-
strand. Several of the residues in the bulge are in contact with VEGF.
NMR analysis of VEGFR-1 domain D2 in the nonliganded state
revealed a structure almost identical with that observed in the
complex crystal structures. Therefore, the different conformations
observed in the aminoterminal bulge have been proposed to arise
from the inherent flexibility of this region, independent of ligand
binding. In addition, an electron microscopy structure of the ligand-
bound ECD of VEGFR-2 was published by our lab. These data show
that receptor dimers are intertwined and form a rigid structure
apparently required to instigate transmembrane signaling [44].
The ectodomains of neuropilins contain two aminoterminal CUB
domains (a1 and a2), two coagulation factor V/VIII homology domains
(b1 and b2) and a singleMAMdomain (meprin, A5, μ-phosphatase; also
known as c) (Fig. 6A) [163,164]. Recently, several crystal structures of
NRP-1 and -2 ectodomain fragments have been reported in their
nonliganded state, in complex with the tuftsin tetrapeptide, and in
complex with antibodies that selectively block either semaphorin or
VEGF-A binding [126,165,166]. These structures have provided a first
picture of the interactions of NRP-1 with its ligands and allowed to
propose models for VEGF, semaphorin and heparin binding.
The NRP-1 b1 and b2 domains are characterized by the typical
discoidin family β-barrel fold [167–169], which consists of a distorted
jellyroll formed by a five- and a three-stranded antiparallel β-sheet
and six loops or spikes (L1–L6) that extend at one end of the β-barrel
(Fig. 6B). In the first reported structure of the NRP-1 b1 domain Lee
and coworkers identified a polar cleft formed by these loops as the
putative binding groove for the positively charged tails of VEGF-A165
and semaphorins [165]. This hypothesis was later confirmed by
Vander Kooi and coworkers with the crystal structures of both the
NRP-1 b1b2 domains in the nonliganded state and in complex with
tuftsin [126]. These structures revealed that the b1b2 domains form a
single structural unit with an unexpected extensive interdomain
interface and provided the first structural details on the interaction of
NRP-1 with VEGF-A [126]. The carboxyterminal arginine (R4) of
tuftsin occupies the acidic cleft and accounts for the majority of the
interactions with NRP-1 b1b2. The side chain of R4 is stacked between
the aromatic rings of Y297 (L1) and Y353 (L3) and forms a salt bridge
Fig. 6. The putative VEGF binding sites on neuropilins. (A) Electrostatic surface potential (calculated with the program DelPhi [171,172]) mapped onto the surfaces of the rat NRP-1
b1b2 (PDB code 2ORZ) and the human NRP-1 a2b1b2 (PDB code 2QQM) and NRP-2 a1a2b1b2 (PDB code 2QQL) domains. The tuftsin binding site and the putative heparin-binding
patch are indicated by black arrows. The tuftsin molecule bound to rat NRP-1 is in green stick representation. The negative (red) and positive (blue) electrostatic surface potentials
are contoured at± 6 kT. (B) Surface representation of hNRP-1 (PDB code 2QQM). The two clusters of residues conserved among neuropilins are highlighted in dark (100% conserved)
and light blue (≥75% conserved), respectively, according to Appleton and coworkers [166].
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to the side chain of D320 (L2). Moreover, the carboxyterminus is
tucked into the pocket and participates in specific interactions with
S346, T349 and Y353 on loop L3.
In all crystal structures that contain both the a and the b domains a
rigid structural unit is formed by the three domains a2, b1 and b2,
which adopt the same arrangement around a pseudo 3-fold axis. The
interdomain interfaces of this tightly packed core are highly
conserved among both neuropilins. In contrast, the domain arrange-
ment between a1 and the a2b1b2 core is not conserved in the two
crystal forms and reveals a high degree of flexibility (Fig. 5C) [166].
The b1 domains of NRP-1 and -2 superimpose with an r.m.s. deviation
of 0.6 Å with the most prominent difference in loop L1 of NRP-2,
which contains an additional aspartic acid residue (D301) compared
to NRP-1. The b2 domains superimpose less well (r.m.s.d. 2.7 Å) due to
larger conformational differences observed in the spikes [166]. These
variations have been implicated in the recognition of multiple binding
partners, as these spikes generally define the binding sites within the
discoidin family. The domains b1 and b2 are tightly packed against
each other with an extensive interdomain interface that contains
predominantly hydrophobic residues, which are highly conserved
among all neuropilins. The interdomain junction forms a deep cleft
that runs approximately perpendicular to the long axis of the two b
domains. This cleft is surrounded by a set of positively charged
residues (R359, K373, R513, K514 and K516), which have been
identified as important for heparin binding based on site-directed
mutagenesis experiments on rat NRP-1 [126]. This electropositive
patch is also conserved in the structures of both human neuropilins
(Fig. 6A). Accordingly, it has been proposed as a putative heparin
binding site [126,166]. Based on sequence conservation analysis
among 12 NRP-1 and -2 proteins Appleton and coworkers identified
two clusters of conserved residues on the b1b2 domains, which map
on the tuftsin binding site and on the edge of the proposed heparin
binding region, suggesting an additional area of interaction between
neuropilin and VEGF-A (Fig. 6B) [166]. The a1a2b1b2 domains of NRP-
2 in complex with antibodies that selectively block either semaphorin
or VEGF-A binding have been crystallized in two different crystal
forms. Both crystal forms contain a conserved crystallographic
interface that is mediated by the a1 domain. Based on the a1-
mediated crystallographic dimers potential models have been
proposed that could accommodate both the dimeric VEGFs or class
3 semaphorins [166].
Several structural studies provide a first detailed picture of both
the VEGF-A and semaphorin binding domains of neuropilins. The
reported structures offer a basis for the design of future crystallo-
graphic approaches to explore the molecular interactions underlying
receptor activation and signaling mediated by VEGFs and semaphor-
ins through both neuropilins. Additional structural information on
complexes of both NRP-1 and -2 bound to different ligands and
peptides will be required for a comprehensive understanding of the
molecular details that define affinities and specificities of the various
neuropilin ligands.
4. Outlook
In the absence of detailed structural information on the interac-
tions of VEGFs with their multidomain receptors it remains unclear
how the observed structural features determine receptor selectivity.
Structural data on receptor–ligand complexes with various VEGF
isoforms are therefore needed to assess the receptor specificity of
VEGF family proteins. We also need more structural information to
clarify the mechanism of VEGFR activation. A promising approach will
be to investigate the extracellular and the intracellular receptor
domains separately as these proteins require different milieus for
proper folding. After assignment of the functions of individual
domains, a comprehensive model for receptor signaling will be
elaborated.
An aspect we did not cover in this article is the question where
ligand-stimulated receptors are located in a cell when relaying their
signals to downstream molecules such as cytoplasmic serine,
threonine or tyrosine kinases of the various subfamilies, to lipid
kinases, phospholipases, or G protein family signaling molecules. It is
this remarkably complex interplay among the diverse signaling
pathways activated by VEGF family proteins that determines signal
specificity and biological output.
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INTRODUCTION: Vascular Endothelial Growth 
Factors (VEGFs) constitute a family of proteins that 
regulate blood and lymphatic vessel development and 
homeostasis. In normal, healthy organisms vessel 
development is tightly regulated to maintain adequate 
blood supply and lymph drainage. Vessels are 
aberrantly stimulated in various diseases such as during 
tumor growth, in atherosclerosis, retinopathies and in 
lymphoproliferative or rheumatoid disease [1]. We are 
investigating the mechanisms responsible for vessel 
formation by VEGF family ligands in vitro using 
endothelial cells grown on micropatterned substrates. 
Patterned substrates are generated to mimic the 
extracellular milieu, in particular the extracellular 
matrix (ECM), of the cells.  
  http://www.ecmjournal.org 
METHODS:  
Protein Immobilization: The ‘Molecular Assembly 
Patterning by Lift-Off (MAPL) technology’ developed 
at ETH Zürich [2] was adapted to the immobilization of 
VEGF. We use the natural affinity of VEGF-A165 to 
heparin for indirect coupling. For this, we incubated 
commercially available heparin-biotin with neutravidin 
and bound the complex to the PLL-g-PEG biotin 
pattern. Further, VEGF-A165 was immobilized via the 
heparin and visualized with an anti-VEGF antibody.  
Cell assay: Porcine Aortic Endothelial (PAE) cells 
expressing the Vascular Endothelial Growth Factor 
Receptor 2 (VEGFR-2) were grown on VEGF patterns. 
Cells were fixed and immunostained with an anti-
VEGFR-2 antibody.  
RESULTS: In our study, we successfully immobilized 
VEGF-A165 on patterned glass coverslips. Visualization 
with an anti-VEGF antibody showed the expected 
pattern (Fig. 1). Furthermore, we demonstrated that 
PAE cells are able to migrate and divide on the 
generated micropatterns (Fig.2).  
 
  
 
 
 
 
 
 
Fig. 1: VEGF-A165 detection on PLL-g-PEG biotin 
patterns. 
 
 
 
 
 
Fig. 2: PAE-VEGFR-2 cells on VEGF-patterned 
coverslips, stained with anti-VEGFR-2 antibody.   
DISCUSSION & CONCLUSIONS: The purpose of 
this study was to establish a technology mimicking the 
extracellular milieu of endothelial cells. We were able 
to grow PAE cells on the heparin/VEGF-A165 coated 
glass support. In a next step, we will culture pluripotent 
mouse stem cells and primary endothelial cells derived 
from human tissues as embryoid bodies [3] on our 
patterned substrates. Various isoforms of VEGF will be 
added as either soluble or matrix-bound material on the 
surface of glass coverslips. Further, we will monitor 
sprouting angiogenesis and vessel formation by live cell 
video microscopy and histologically after fixation. 
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